Treatment of gastric cancer
By using anti-FGFR2b antibodies in combination with chemotherapy drugs oxaliplatin and capecitabine or S-1, targeting gastric cancer cells that overexpress FGFR2b, the problem of poor treatment efficacy for gastric cancer has been solved, and the survival rate and symptom relief of advanced gastric cancer have been improved.
Patent Information
- Application Number
- CN202380032385.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-03-24
- Filing Date
- 2023-04-04
- Publication Date
- 2024-11-26
AI Technical Summary
Treatment outcomes for gastric cancer are poor, especially for advanced gastric cancer. Current treatments lack effective targeted therapies, and patients with low PD-L1 composite positive scores do not benefit significantly. New treatment targets and methods are needed.
Anti-FGFR2b antibodies, combined with chemotherapy regimens such as oxaliplatin and capecitabine or S-1, are used to target gastric cancer cells that overexpress FGFR2b. The antibodies and chemotherapy drugs are administered intravenously or orally to enhance the treatment effect.
It significantly improved the survival rate and symptom relief of advanced gastric cancer, enhanced the inhibitory effect on FGFR2b overexpressing cells, provided a new therapeutic target, and improved the challenge of treatment.
Smart Images

Figure CN119032107A_ABST
Abstract
Description
Technical Field
[0001] The embodiments herein relate to the use of antibodies against fibroblast growth factor 2 (FGFR2), including antibodies against FGFR2 isoform FGFR2-IIIb (also referred to as FGFR2b), in treating gastric cancer, such as gastric adenocarcinoma and gastroesophageal junction adenocarcinoma.
[0002] Incorporation by Reference of Electronically Submitted Materials
[0003] Incorporated herein by reference in its entirety is the Nucleotide / Amino Acid Sequence Listing filed concurrently herewith and identified as follows: a 13,841-byte XML document named "10130-WO01-SEC.xml", created on March 27, 2023.
[0004] CROSS-REFERENCE TO RELATED APPLICATIONS
[0005] This application claims the benefit of U.S. Provisional Application No. 63 / 327,666, filed on April 5, 2022, and U.S. Provisional Application No. 63 / 491,969, filed on March 24, 2023, the disclosures of which are incorporated herein by reference. Background Art
[0006] Gastric cancer (GC) is the fifth most common cancer worldwide, with more than 1 million new cases each year worldwide (Bray et al., 2018). The highest incidence rates are in China, Japan, Latin America, and Eastern Europe (>20 / 100,000 in men), while the lowest incidence rates are in North America, parts of Africa, and Northern Europe (<10 / 100,000 in men). Only 27% of newly diagnosed GCs are localized and advanced disease has a poor prognosis, and treatment remains challenging, with a 5-year overall survival (OS) rate of <5%, and no significant benefit for patients with tumors with a programmed death receptor 1 (PD-L1) composite positive score (CPS) <5 (hazard ratio [HR] = 0.94 [95% CI: 0.78 to 1.14]). Therefore, despite a decline in the incidence of GC, it remains a serious health burden worldwide with a high mortality rate.
[0007] Fibroblast growth factor receptor 2b (FGFR2b) is present in most gastric cancers (GC) and is a target for novel therapies that can improve treatment outcomes. Fibroblast growth factor (FGF) family members bind to four known tyrosine kinase receptors, i.e., fibroblast growth factor receptors 1-4 (FGFR1 4) and isoforms thereof, and various FGFs bind to different FGFRs (Zhang et al., J.Biol.Chem. [Journal of Biological Chemistry] 281:15694, 2006) to varying degrees. The protein sequence of human FGFR2 is provided in, for example, GenBank locus AF487553. Each FGFR is composed of an extracellular domain (ECD) comprising three immunoglobulin (Ig)-like domains (D1, D2, and D3), a single transmembrane helix, and an intracellular catalytic kinase domain (Mohammadi et al., Cytokine Growth Factor Revs [Cytokine and Growth Factor Review], 16:107, 2005). FGF binds to the receptor primarily through regions in D2 and D3 of the receptor. There is a stretch of consecutive acidic amino acids in the linker between D1 and D2, called the "acid box" (AB). The region containing D1 and AB is thought to be involved in the autoinhibition of the receptor, which is relieved by binding to the ligand.
[0008] The characteristic of FGFR is that its mRNA undergoes multiple alternative splicing, thereby producing a variety of isoforms (Ornitz et al., J. Biol. Chem. [Journal of Biological Chemistry] 271: 15292, 1996; also see Swiss-Prot P21802 and isoforms P21802-1 to -20 for the sequences of FGFR2 and its isoforms). It should be noted that there are forms containing all three Ig domains (α isoforms) or only two Ig domains D2 and D3 domains without D1 (β isoforms). In FGFR1, FGFR2 and FGFR3, all forms contain the first half of D3 (denoted as IIIa), but two alternative exons can be used for the second half of D3, thereby producing IIIb and IIIc forms. For FGFR2, these forms are respectively expressed as FGFR2-IIIb and FGFR2-IIIc (or respectively expressed as only FGFR2b and FGFR2c); The corresponding β forms are expressed as FGFR2 (β) IIIb and FGFR2 (β) IIIc. The FGFR2-IIIb form of FGFR2 (also expressed as K-sam-II) is a high affinity receptor for FGF1 and KGF family members (FGF7, FGF10 and FGF22), while FGFR2-IIIc (also expressed as K-sam-I) is well combined with FGF1 and FGF2 but not with KGF family members (Miki et al., Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 89: 246, 1992). In fact, FGFR2-IIIb is the only receptor for KGF family members (Ornitz et al., 1996, supra), and is therefore also referred to as KGFR.
[0009] FGFR and its isoforms are differentially expressed in various tissues. FGFR2-IIIb (and IIIb forms of FGFR1 and FGFR3) are expressed in epithelial tissues, while FGFR2-IIIc is expressed in interstitial tissues (Duan et al., J.Biol.Chem. [Journal of Biological Chemistry] 267:16076, 1992; Ornitz et al., 1996, ibid). Some FGF ligands of these receptors have opposite expression patterns. Therefore, KGF subfamily members (including FGF7 (KGF), FGF10 and FGF22) are only combined with FGFR2-IIIb (Zhang et al., ibid) and expressed in interstitial tissues, so they may be paracrine effectors of epithelial cells (Ornitz et al., 1996, ibid). In contrast, FGF4 subfamily member FGF4-6 is combined with FGFR2-IIIc and expressed in epithelial and interstitial lineages, so it may have autocrine or paracrine functions. Given the expression pattern of FGFR2 isoforms and their ligands, FGFR2 plays a role in epithelial-mesenchymal interactions (Finch et al., Dev. Dyn. 203:223, 1995), so it is not surprising that knockout of FGFR2-IIIb in mice results in severe embryonic defects and lethality (De Moerlooze et al., Development 127:483, 2000). Summary of the invention
[0010] The present disclosure provides a method of treating gastric cancer in a subject, the method comprising administering to the subject an anti-FGFR2b antibody; and administering to the subject a chemotherapy regimen comprising: (a) oxaliplatin and capecitabine; or (b) oxaliplatin and S-1.
[0011] In some embodiments of the above methods, the anti-FGFR2b antibody is administered Q3W at a dose of at least 15 mg / kg.
[0012] In some embodiments of the above methods, the anti-FGFR2b antibody is administered Q3W at a dose of 15-22 mg / kg or greater than 15 mg / kg to no more than 22 mg / kg.
[0013] In some embodiments, the above methods further comprise administering an additional dose of 5-15 mg / kg of the anti-FGFR2b antibody 7-10 days after the first Q3W administration of the anti-FGFR2b antibody.
[0014] In some embodiments of the above methods, the additional dose of anti-FGFR2b antibody is 6-9 mg / kg or 7-8 mg / kg.
[0015] In some embodiments of the above methods, the anti-FGFR2b antibody is administered Q3W at a dose of at least 20 mg / kg.
[0016] In some embodiments of the above methods, the anti-FGFR2b antibody is administered Q3W at a dose of 20-30 mg / kg or 22-25 mg / kg or greater than 22 mg / kg to no more than 30 mg / kg or greater than 22 mg / kg to no more than 25 mg / kg.
[0017] In some embodiments, the above methods further comprise administering an additional dose of 10-15 mg / kg of the anti-FGFR2b antibody 7-10 days after the first Q3W administration of the anti-FGFR2b antibody.
[0018] In some embodiments of the above methods, the additional dose of anti-FGFR2b antibody is 9-13 mg / kg or 10-12 mg / kg.
[0019] In some embodiments of the above methods, the anti-FGFR2b antibody is administered intravenously.
[0020] In some embodiments, the above method further comprises administering at least 65 mg / m 2 Oxaliplatin is administered intravenously every 3 weeks at a dose of at least 500 mg / m 2 Capecitabine was administered orally at a dose of twice a day.
[0021] In some embodiments of the above methods, oxaliplatin is administered at 100-150 mg / m 2 The dose was administered intravenously Q3W, and capecitabine was administered at 750-1500 mg / m 2 The dose is administered orally twice a day.
[0022] In some embodiments, the method further comprises administering at least 65 mg / m 2 Oxaliplatin is administered intravenously every 3 weeks at a dose of at least 20 mg / m 2 The dosage of S-1 was administered orally twice a day.
[0023] In some embodiments of the above methods, oxaliplatin is administered at 100-150 mg / m 2 The dose is administered intravenously Q3W, and S1 is administered at 30-60 mg / m 2 The dose is administered orally twice a day.
[0024] In some embodiments of the above methods, the anti-FGFR2b antibody is administered intravenously at a dose of 15-22 mg / kg Q3W, and further administered at an additional dose of 7-12 mg / kg 7-10 days after the first Q3W administration of the anti-FGFR2b antibody, and the chemotherapy regimen comprises: (a) 100-150 mg / m 2 The oxaliplatin was administered intravenously at a dose of 750-1500 mg / m 2 or (b) administering capecitabine orally twice a day at a dose of 10-150 mg / m 2 The oxaliplatin was administered intravenously at a dose of 30-60 mg / m 2 The S-1 was administered orally at a dosage of twice a day.
[0025] In some embodiments of the above methods, the anti-FGFR2b antibody is administered intravenously at a dose of 15-22 mg / kg Q3W, and is further administered at an additional dose of 7-12 mg / kg 7-10 days after the first administration of the anti-FGFR2b antibody in the Q3W regimen, and the chemotherapy regimen comprises: (a) 130 mg / m 2 The oxaliplatin was administered intravenously at a dose of 1000 mg / m 2 The capecitabine is administered orally twice a day at a dose of 130 mg / m 2 The oxaliplatin was administered intravenously at a dose of 40 mg / m 2 The S-1 was administered orally at a dosage of twice a day.
[0026] In some embodiments of the above methods, the anti-FGFR2b antibody is administered intravenously at a dose of 22-30 mg / kg Q3W and further administered at an additional dose of 10-12 mg / kg 7-10 days after the first Q3W administration of the anti-FGFR2b antibody, and the chemotherapy regimen comprises: (a) 130 mg / m 2 The oxaliplatin was administered intravenously at a dose of 1000 mg / m 2 The capecitabine is administered orally twice a day at a dose of 130 mg / m 2 The oxaliplatin was administered intravenously at a dose of 40 mg / m 2 The S-1 was administered orally at a dosage of twice a day.
[0027] In some embodiments, the above methods further comprise administering an anti-PD-1 or anti-PD-L1 antibody to the subject.
[0028] In some embodiments of the above methods, the anti-PD-1 or anti-PD-L1 antibody is administered Q3W.
[0029] In some embodiments of the above methods, the anti-PD-1 antibody comprises nivolumab, pembrolizumab, or orcemiplimab, or the anti-PD-L1 antibody comprises atezolizumab, avelumab, or durvalumab.
[0030] In some embodiments, the above methods further comprise administering nivolumab to the subject at a dose of at least 300 mg Q3W.
[0031] In some embodiments of the above methods, nivolumab is administered at a dose of 300 mg-400 mg Q3W.
[0032] In some embodiments of the above methods, nivolumab is administered at a dose of 360 mg Q3W.
[0033] In some embodiments of the above methods, the anti-FGFR2b antibody comprises a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO:6, HCDR2 of SEQ ID NO:7, and HCDR3 of SEQ ID NO:8; and a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO:9, LCDR2 of SEQ ID NO:10, and LCDR3 of SEQ ID NO:11.
[0034] In some embodiments of the above methods, the anti-FGFR2b antibody is afucosylated.
[0035] In some embodiments of the above methods, the heavy chain variable region of the FGFR2b antibody comprises an amino acid sequence at least 95% identical to SEQ ID NO:4, and the light chain variable region of the anti-FGFR2b antibody comprises an amino acid sequence at least 95% identical to SEQ ID NO:5.
[0036] In some embodiments of the above methods, the heavy chain variable region of the anti-FGFR2b antibody comprises the amino acid sequence of SEQ ID NO:4, and the light chain variable region of the anti-FGFR2b antibody comprises the amino acid sequence of SEQ ID NO:5.
[0037] In some embodiments of the above methods, the anti-FGFR2b antibody comprises a heavy chain of SEQ ID NO:1 and a light chain of SEQ ID NO:2.
[0038] In some embodiments of the above methods, the anti-FGFR2b antibody is bemarituzumab.
[0039] In some embodiments of the above methods, gastric cancer cells overexpress FGFR2b.
[0040] In some embodiments of the above methods, gastric cancer cells overexpress FGFR2b mRNA or protein, or contain FGFR2 gene amplification.
[0041] In some embodiments of the above methods, cells of gastric cancer overexpress FGFR2b as determined by immunohistochemistry (IHC).
[0042] In some embodiments of the above methods, at least 5%, 10%, 15% or 20% of the cells of the gastric cancer express FGFR2b as determined by IHC.
[0043] In some embodiments of the above methods, the gastric cancer cells have a FGFR2b staining intensity of at least 2+ or 3+, as determined by IHC, such as at least 5%, 10%, 15% or 20% of the gastric cancer cells have said FGFR2b staining intensity.
[0044] In some embodiments of the above methods, the subject's gastric cancer overexpresses FGFR2b as determined by FGFR2b staining intensity of at least 2+ or 3+ in any cell of the gastric cancer sample, as determined by IHC.
[0045] In some embodiments of the above methods, the subject's gastric cancer overexpresses FGFR2b as determined by FGFR2b staining intensity of at least 2+ or 3+ in at least 10% of cells in the gastric cancer sample, as determined by IHC.
[0046] In some embodiments of the above methods, the gastric cancer comprises gastric cancer or gastroesophageal junction cancer.
[0047] In some embodiments of the above methods, the chemotherapy regimen comprises (a) oxaliplatin and capecitabine. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1 It is a diagram of a method for treating gastric cancer.
[0049] Figure 2A -B is a diagram of the amino acid sequence. Figure 2A The amino acid sequences of the anti-FGFR2b antibodies of some embodiments are depicted. Figure 2B The amino acid sequences of FGFR2 of some embodiments are depicted. DETAILED DESCRIPTION
[0050] Described herein is a method for treating gastric cancer in a subject. The cells of gastric cancer can overexpress FGFR2 isoform FGFR2-IIIb (also referred to as FGFR2b). These methods can include administering anti-FGFR2b antibodies, such as bemarituzumab, to the subject. These methods can further include administering chemotherapy regimens, such as oxaliplatin and capecitabine (CAPOX) or oxaliplatin and S-1 (SOX). Anti-FGFR2b antibodies can be administered in the same composition with CAPOX or SOX, or can be administered (sequentially or simultaneously) in a separated composition. It can be envisioned herein that the administration of anti-FGFR2b antibody monotherapy can be consistent with CAPOX and SOX regimens (usually once every three weeks (Q3W)). For example, an anti-FGFR2b antibody can be administered to a subject at a dose of at least 15 mg / kg (such as 15-22 mg / kg, greater than 15 mg / kg to no more than 22 mg / kg, 20-30 mg / kg, 22-25 mg / kg, greater than 22 mg / kg to no more than 30 mg / kg, or greater than 22 mg / kg to no more than 25 mg / kg) Q3W. For example, an anti-FGFR2b antibody can be administered to a subject at a dose of at least 15 mg / kg or at least 20 mg / kg Q3W. In some embodiments, these methods may further include administering an additional dose of about 5-15 mg / kg of anti-FGFR2b antibody to the subject 7-10 days after the first Q3W administration of the anti-FGFR2b antibody. For example, the additional dose of the anti-FGFR2b antibody can be about 10-15 mg / kg (e.g., 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, or 15 mg / kg) administered 7-10 days after the first Q3W administration of the anti-FGFR2b antibody. For example, the anti-FGFR2b antibody can be administered to the subject at a dose of at least 15 mg / kg (e.g., 15-22 mg / kg) in the first administration and at an additional dose of 5-15 mg / kg (e.g., 6-9 mg / kg, 7-8 mg / kg, 9-13 mg / kg, or 10-12 mg / kg) of the anti-FGFR2b antibody Q3W 7-10 days after the first administration of the anti-FGFR2b antibody.
[0051] The administration schedule of the anti-FGFR2b antibody can be synchronized with the administration schedule of oxaliplatin and capecitabine (CAPOX) or oxaliplatin and S-1 (SOX), thereby minimizing the number of administration sites for the subject.
[0052] Fibroblast growth factor receptor 2b (FGFR2b) is present in the majority of gastric cancers. Although results vary significantly depending on the assay used and tumor stage, up to 61% of gastric cancer patients have reportedly FGFR2b-overexpressing tumors (Ahn et al., 2016; Tokunaga et al., 2016; Han et al., 2015). Fibroblast growth factor receptor (FGFR) signaling plays an important role in cell growth and survival (Katoh and Katoh, 2006).
[0053] A recent study evaluating the pathological and prognostic significance of FGFR2 overexpression in gastric cancer patients (including 4294 patients from 10 studies) found that FGFR2-overexpressing gastric cancer was associated with significantly worse survival compared with tumors showing low FGFR2 expression (HR = 1.40, 95% CI: 1.25 to 1.58; p < 0.00001) (Kim et al., 2019), suggesting that inhibition of FGFR2b may be an important therapeutic target (Jung et al., 2012; Matsumoto et al., 2012).
[0054] Chemotherapy for advanced gastric cancer prolongs survival and improves symptoms (Waddell et al., 2014; Kang et al., 2009; Okines et al., 2009; Al-Batran et al., 2008; Wagner et al., 2006). The combination of platinum agents and fluoropyrimidines has become a commonly used combination (Kang et al., 2009) and has been determined to be superior to single-agent treatment and best supportive care in a recent meta-analysis (Wagner et al., 2006). Although there is no globally recognized single standard first-line reference chemotherapy regimen for advanced gastric cancer, the combination of fluoropyrimidines (5-FU, capecitabine or S-1) and platinum agents (cisplatin or oxaliplatin) is a recognized standard of care in Western and Asian countries (Kang et al., 2009; Okines et al., 2009; Al-Batran et al., 2008; Keam et al., 2008; Wagner et al., 2006).
[0055] Anti-FGFR2b Antibodies
[0056] As used herein, "antigen binding protein" has its customary and common meaning, as understood by those of ordinary skill in the art in view of the present disclosure. It refers to a protein that specifically binds to a specific antigen. The term encompasses complete antibodies and their derivatives, variants, fragments and mutants. Antigen binding proteins also include bivalent and multivalent (polyvalent / multivalent) constructs and bispecific and multispecific (polyspecific / multispecific) constructs, as well as domain antibodies, scFvs, and membrane-bound receptors and soluble receptors. In some embodiments, the antigen binding protein comprises, is essentially composed of, or is composed of an antibody. In any of the methods described herein, an anti-FGFR2b antigen binding protein can be administered to a subject. For example, an antigen binding protein can include an antibody (e.g., bemarituzumab) or be composed of an antibody.
[0057] Antibodies are examples of antigen-binding proteins. As used herein, "antibodies" have their customary and common meanings, as understood by those of ordinary skill in the art in view of the present disclosure. It refers to an immunoglobulin of any isotype that specifically binds to a target antigen, and includes, for example, chimeric antibodies, humanized antibodies, fully human antibodies, and monoclonal antibodies. "Antibodies" are thus a subgenus of an antigen-binding protein. For example, human antibodies or humanized antibodies can be of any isotype, including IgG (including IgG1, IgG2, IgG3, and IgG4 subtypes), IgA (including IgA1 and IgA2 subtypes), IgM, and IgE. Human IgG antibodies will typically contain two full-length heavy chains and two full-length light chains. Antibodies can be derived from a single source only, or can be "chimeric" antibodies, i.e., different parts of an antibody may be derived from two or more different antibodies of the same or different species. It should be understood that once an antibody is obtained from a source, it can be further engineered, for example to enhance stability and folding. Therefore, it should be understood that "human" antibodies can be obtained from a source and can undergo further engineering, such as engineering in the Fc region. Engineered antibodies can still be referred to as a type of human antibody. Similarly, variants of human antibodies, such as those that have undergone affinity maturation, will also be understood to be "human antibodies" unless otherwise specified. In some embodiments, the antigen binding protein comprises, consists essentially of, or consists of a human antibody, a humanized antibody, or a chimeric monoclonal antibody.
[0058] The "heavy chain" of an antigen binding protein (such as an antibody) includes a variable region ("VH") and three constant regions: CH1, CH2 and CH3. The "light chain" of an antigen binding protein (such as an antibody) includes a variable region ("VL") and a constant region ("CL"). Human light chains include kappa chains and lambda chains.
[0059] "Antigen binding region" means a protein or protein portion that specifically binds to a specific antigen. For example, the portion of an antigen binding protein that contains amino acid residues that interact with an antigen and give the antigen binding protein its specificity and affinity for the antigen is called an "antigen binding region". The antigen binding region typically comprises one or more "complementary binding regions" ("CDRs") of an antibody. "CDRs" are amino acid sequences that contribute to antigen binding specificity and affinity. The antigen binding regions of antibody heavy and light chains typically exhibit the same overall structure, comprising a relatively conservative framework region (FR) connected by three CDRs. The CDRs from the two chains of each heavy chain / light chain pair are typically aligned by the framework region to form a structure that specifically binds to a specific epitope on the target protein. From the N-terminus to the C-terminus, naturally occurring light and heavy chain variable regions typically conform to the following order of these elements: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The numbering system has been designed to assign numbers to the amino acids that occupy positions in each of these domains. This numbering system is defined in Kabat, Sequences of Proteins of Immunological Interest (1987 and 1991, National Institutes of Health, Bethesda, Md.); or Chothia and Lesk, 1987, J. Mol. Biol. 196:901-917; Chothia et al., 1989, Nature 342:878-883. In some embodiments, the CDRs of an antigen binding protein are defined according to the definition of Kabat or Chothia.
[0060] Anti-FGFR2b antigen binding proteins (such as antibodies) can be used in the methods described herein.Antibodies can specifically bind to FGFR2b.In the methods of some embodiments, anti-FGFR2b antigen binding proteins bind to FGFR2b with a higher affinity than binding to FGFR2-IIIc.For example, the binding of anti-FGFR2b antibodies to FGFR-IIIc may not be detected.In the methods of some embodiments, anti-FGFR2b antigen binding proteins (e.g., antibodies) bind to FGFR2b, and block or inhibit signal transduction by FGFR2b receptors.For example, the binding of anti-FGFR2b antigen binding proteins (e.g., antibodies) to FGFR2b can inhibit the phosphorylation of MAP kinases downstream of FGFR2 or FGFR2.In the methods of some embodiments, anti-FGFR2b antigen binding proteins (e.g., antibodies) inhibit the binding between FGFR2b and its FGF ligands (such as FGF1 and / or FGF2) after binding to FGFR2b.
[0061] The binding of antigen binding proteins (e.g., antibodies) to FGFR2b and the inhibition of the binding between FGFR2b and FGF can be evaluated, for example, by the ELISA assay described in U.S. Patent No. 8,101,723 or, for example, by the chip-based assay described in Example 2 of WO 2015 / 017600. In some embodiments, the antibody induces ADCC activity, and in some embodiments has enhanced ADCC activity (e.g., as described in WO 2015 / 017600). For example, ADCC activity can be measured as described in Example 3 of WO2015 / 07600. In some embodiments, the antibody can inhibit the growth of human tumors in mouse models, for example, as shown in Example 1 of WO 2017 / 091577. In some embodiments, the anti-FGFR2-IIIb antibody is capable of increasing the number of one or more of PD-L1 positive cells, NK cells, CD3+T cells, CD4+T cells, CD8+T cells and macrophages in tumor tissue in a mouse tumor model compared to a control, for example, as described in Example 2 of International Application No. WO 2017 / 091577.
[0062] Any anti-FGFR2b antibody described herein can be afucosylated. For example, the antibody can be an IgG1 or IgG3 antibody lacking fucose at Asn297. As used herein, an "afucosylated" antibody or an antibody "lacking fucose" refers to an IgG1 or IgG3 isotype antibody lacking fucose in its constant region glycosylation. Glycosylation of human IgG1 or IgG3 occurs at Asn297 (N297; EU numbering of Fc region residues), and the core fucosylated bi-branched complex oligosaccharide glycosylation terminates with up to 2 Gal residues. In some embodiments, the afucosylated antibody lacks fucose at Asn297. Depending on the number of terminal Gal residues, these structures are named G0, G1 (α1,6 or α1,3) or G2 glycan residues. See, for example, Raju, TS, BioProcess Int. [International Journal of Biopharmaceutical Engineering Technology] 1: 44-53 (2003). CHO-type glycosylation of antibody Fc is described, for example, in Routier, FH, Glycoconjugate J. 14:201-207 (1997). It will be appreciated that compositions comprising monoclonal antibodies are typically heterogeneous. Indeed, the methods comprising administering the afucosylated anti-FGFR2 antibodies described herein may also comprise administering some afucosylated antibody molecules. Within a population of antibodies, an antibody is considered afucosylated if <5% of the antibodies in the population contain fucose at Asn297. For example, in some embodiments, greater than 95% of the anti-FGFR2b antibody molecules administered to a subject are afucosylated. For example, in some embodiments, at least 96%, 97%, or 99% of the anti-FGFR2b antibody molecules administered to a subject may be afucosylated. Other antibodies useful in the examples herein include those described in U.S. Patent Publication No. 2015 / 0050273, which describes certain afucosylated anti-FGFR2b antibodies and is incorporated herein by reference in its entirety.
[0063] In some embodiments, in the presence of human effector cells, the afucosylated anti-FGFR2b antibody mediates antibody-dependent cell-mediated cytotoxicity (ADCC) more effectively than an antibody comprising fucose having the same amino acid sequence. Typically, ADCC activity can be determined using an in vitro ADCC assay disclosed in U.S. Patent Publication No. 2015 / 0050273, but other assays or methods for determining ADCC activity, such as in animal models, are contemplated.
[0064] Exemplary sequences of anti-FGFR2b antibodies of some embodiments are Figure 2AIn some embodiments of the method, the anti-FGFR2b antibody comprises at least one, two, three, four, five or six complementary determining regions (CDRs) selected from (a) HCDR1 of SEQ ID NO: 6; (b) HCDR2 of SEQ ID NO: 7; (c) HCDR3 of SEQ ID NO: 8; (d) LCDR1 of SEQ ID NO: 9; (e) LCDR2 of SEQ ID NO: 10; and (f) LCDR3 of SEQ ID NO: 11. Anti-FGFR2b may comprise a heavy chain comprising a heavy chain variable region comprising HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8; and may further comprise a light chain comprising a light chain variable region comprising LCDR1 of SEQ ID NO: 9, LCDR2 of SEQ ID NO: 8, and LCDR3 of SEQ ID NO: 9. In some embodiments of the method, the heavy chain variable region is at least 90% identical to SEQ ID NO: 4, and the light chain variable region is at least 90% identical to SEQ ID NO: 5. In some embodiments of the method, the heavy chain variable region is at least 95% identical to SEQ ID NO: 4, and the light chain variable region is at least 95% identical to SEQ ID NO: 5. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 4, and the light chain variable region comprises SEQ ID NO: 5. In some embodiments of the method, the heavy chain comprises SEQ ID NO: 2, and the light chain comprises SEQ ID NO: 3. Any anti-FGFR2 antibody described herein can be afucosylated. For example, the antibody can be an IgG1 or IgG3 antibody lacking fucose at Asn297. In some embodiments of the method, the anti-FGFR2b antibody is bemarituzumab.
[0065] In some embodiments of the method, the anti-FGFR2b antibody comprises a heavy chain variable region comprising SEQ ID NO: 4 and a light chain variable region comprising SEQ ID NO: 5. It is also contemplated that in some embodiments, the anti-FGFR2b antibody comprises one or more substitutions, insertions or deletions compared to SEQ ID NO: 4 and / or SEQ ID NO: 5, and continues to bind to FGFR2b. For example, the anti-FGFR2b antibody comprises one or more substitutions, insertions or deletions compared to SEQ ID NO: 4 and / or SEQ ID NO: 5, and can bind to FGFR2b with an affinity (as measured by surface plasmon resonance) that is not less than one order of magnitude lower than the affinity of a reference FGFR2b antibody, the reference antibody comprising a heavy chain variable region comprising SEQ ID NO: 4 and a light chain variable region comprising SEQ ID NO: 5. In some embodiments of the methods, the anti-FGFR2b antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 96%, 98% or 99% identity to SEQ ID NO: 4, and the light chain variable region having at least 90% identity to SEQ ID NO: 5. In some embodiments of the methods, the anti-FGFR2b antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 96%, 98% or 99% identity to SEQ ID NO: 4, and the light chain variable region having at least 91% identity to SEQ ID NO: 5. In some embodiments of the methods, the anti-FGFR2b antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 96%, 98% or 99% identity to SEQ ID NO: 4, and the light chain variable region having at least 95% identity to SEQ ID NO: 5. In some embodiments of the methods, the anti-FGFR2b antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 96%, 98% or 99% identity to SEQ ID NO: 4, and the light chain variable region having at least 97% identity to SEQ ID NO: 5. In some embodiments of the methods, the anti-FGFR2b antibody comprises a heavy chain variable region and a light chain variable region of SEQ ID NO:5, wherein the heavy chain variable region is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 96%, 98% or 99% identical to SEQ ID NO:4.In the methods of some embodiments, the anti-FGFR2b antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region having at least 90% identity with SEQ ID NO: 4, and the light chain variable region having at least 90% identity with SEQ ID NO: 5. In the methods of some embodiments, the heavy chain variable region has at least 95% identity with SEQ ID NO: 4, and the light chain variable region has at least 95% identity with SEQ ID NO: 5. In some embodiments, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 4. Substitutions, insertions or deletions may occur in regions other than CDRs (i.e., in FRs). In the methods of some embodiments, a total of 1 to 10, 1 to 5, or 1 to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 5. Substitutions, insertions or deletions may occur in regions other than CDRs (i.e., in FRs). In some embodiments, a total of 1 to 10, 1 to 5, or 1 to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 4. Substitutions, insertions or deletions may occur in regions outside the CDRs (i.e., in the FRs). In the methods of some embodiments, up to 10, up to 5, or up to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:5, and up to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:4. Substitutions, insertions or deletions may occur in regions outside the CDRs (i.e., in the FRs). In the methods of some embodiments, up to 10, up to 5, or up to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:5, and up to 5 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:4. Substitutions, insertions or deletions may occur in regions outside the CDRs (i.e., in the FRs). In the methods of some embodiments, up to 10, up to 5, or up to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:5, and up to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:4. Substitutions, insertions or deletions may occur in regions other than CDRs (i.e., in FRs). In some embodiments, a total of 1 to 10, 1 to 5, or 1 to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 4. Any anti-FGFR2 antibody described herein may be afucosylated. For example, the antibody may be an IgG1 or IgG3 antibody lacking fucose at Asn297.
[0066] Other examples of anti-FGFR2b antibodies are HuGAL-FR21, GAL-FR22 and GAL-FR23 antibodies described in U.S. Patent No. 8,101,723B2, which is incorporated herein by reference in its entirety. Figures 13 and 14 of U.S. Patent No. 8,101,723B2 show the amino acid sequences of the variable regions and full-length mature antibody chains of HuGAL-FR21, and are incorporated herein by reference. The heavy chain variable region sequence of antibody HuGAL-FR21 is underlined in Figure 13 of U.S. Patent No. 8,101,723B2, and is expressly incorporated herein by reference. The light chain and heavy chain variable regions of GAL-FR22 are provided as (e.g.) SEQ ID NOs: 7 and 8 in patent No. 8,101,723B2, and Kabat CDRs and light chain and heavy chain variable regions are also provided in Figure 16 of the patent, which is incorporated herein by reference. The hybridomas producing GAL-FR21, GAL-FR22, and GAL-FR23 were deposited with the American Type Culture Collection, PO Box 1549, Manassas VA, USA, 20108, on November 6, November 6, and August 12, 2008, under ATCC Nos. 9586, 9587, and 9408, respectively. Thus, in some embodiments, the FGFR2 antibody is an antibody comprising the amino acid sequence of an antibody obtained from one of these three hybridoma strains.
[0067] Bemarituzumab is a non-fucosylated humanized monoclonal antibody that targets fibroblast growth factor (FGF) receptor isoform 2b (FGFR2b) and has a dual mechanism of FGF binding inhibition and antibody-dependent cellular toxicity. The anti-FGFR2b antibody of any one of the methods described herein can be bemarituzumab. Bemarituzumab comprises a heavy chain of SEQ ID NO:2 and a light chain of SEQ ID NO:3. In the methods of some embodiments, the anti-FGFR2 antibody comprises a heavy chain of SEQID NO:2 and a light chain of SEQ ID NO:3, and is non-fucosylated. In the methods of some embodiments, the anti-FGFR2b antibody is bemarituzumab. In the methods of some embodiments, the anti-FGFR2b antibody comprises HCDR1-3 and LCDR1-3 of bemarituzumab. Bemarituzumab can be produced in a Chinese hamster ovary cell line lacking the FUT8 gene, so the produced antibody is glycosylated but lacks core fucose in the polysaccharide portion of the antibody. The absence of core fucose results in a higher affinity for the Fc receptor FcγRIIIa compared to the fucosylated molecule and potentially enhances immune cell-mediated tumor cell killing.
[0068] In cell culture of FGFR2b overexpressing gastric cancer cell lines and breast cancer cell lines, bemarituzumab inhibits FGF ligand-stimulated FGFR2b phosphorylation and cell proliferation. Bemarituzumab also inhibits tumor growth in FGFR2b overexpressing gastric and breast xenograft models. Without being limited by theory, it is conceivable that the mechanism of action of bemarituzumab may include blocking ligand binding and downstream signaling, reducing the expression of FGFR2b driver proteins and / or enhancing ADCC. In addition, without being limited by theory, it is conceivable that because bemarituzumab is specific to FGFR2b receptors, it will not interfere with the signaling of other FGF / FGFRs (including FGFR2c). Compared with FGFR tyrosine kinase inhibitors (TKIs), bemarituzumab does not inhibit FGF23 signaling. FGF23 is a ligand involved in calcium / phosphate metabolism, so treatment with bemarituzumab is not associated with hyperphosphatemia associated with FGFR TKIs (Catenacci et al., 2020; Dienstmann et al., 2014; Sequist et al., 2014; Andre et al., 2013; Brown et al., 2005).
[0069] Bemarituzumab monotherapy has been studied in a Phase 1 dose-finding study (FPA144-001) and in combination with mFOLFOX6 chemotherapy in FGFR2b-positive gastric cancer in the FIGHT study. The efficacy of bemarituzumab correlates with the degree of FGFR2b overexpression in gastric cancer as detected by immunohistochemistry (IHC), and has demonstrated a manageable safety profile in combination with mFOLFOX6. Genomic and IHC data suggest that other carcinomas, including gastric cancer, may also have significant rates of FGFR2b overexpression.
[0070] Bemarituzumab blocks FGFR2b phosphorylation, downregulates the receptor, and inhibits downstream signaling. The effects on downstream signaling were measured by studying the phosphorylation of proteins directly phosphorylated by the FGFR2 protein, FGFR substrate-2 (FRS2). Each of these mechanisms has been explored in vitro and in vivo, and without being limited by theory, appears to contribute to the antitumor activity of bemarituzumab. In human tumor xenograft models with overexpression of FGFR2b, bemarituzumab showed dose-related antitumor activity, with regressions and complete responses at well-tolerated doses.
[0071] Bemmarituzumab exhibited consistent pharmacokinetic (PK) behavior following intravenous (IV) administration in rats and cynomolgus monkeys, and the PK profiles observed were consistent across all studies. The half-life was dose-dependent, ranging from 0.8 days at the lowest dose (1 to 1.5 mg / kg) to at least 8 days at the highest dose (100 to 150 mg / kg) tested in cynomolgus monkeys. Bemmarituzumab exhibited dose-dependent, nonlinear PK, marked by faster clearance at the end of the plasma concentration-time profile and greater than dose-proportional increases in exposure (area under the concentration-time curve [AUC]) with increasing doses. Target-mediated clearance was saturable, marked by dose-proportional increases in exposure at doses above this level when administered at weekly intervals. PK studies supporting the toxicokinetic studies showed a dose-dependent increase in exposure (AUC), supporting the reliability of these studies in assessing toxicity. Through prenatal and postnatal development studies, significant reproductive and developmental toxicity was observed at all dose levels (5 to 100 mg / kg / dose) in embryo-fetal development. Thus, it is conceivable that, in some embodiments, subjects treated with bemarituzumab do not become pregnant.
[0072] Bemarituzumab has demonstrated an acceptable safety profile. Identified risks when used in combination with mFOLFOX6 include corneal toxicity, infusion-related reactions, gastrointestinal toxicity (stomatitis and mucosal inflammation), nail toxicity, and elevated AST and ALT. Corneal events seen with bemarituzumab treatment are very common, with the most common adverse event being dry eye. Although almost all events are non-serious, grade 3 events (such as ulcerative keratitis and punctate keratitis) have been observed, which can lead to decreased visual acuity. Most corneal events are usually resolved with interruption or discontinuation of treatment and standard care interventions for corneal events. Thus, it is conceivable that, in some embodiments, subjects treated with bemarituzumab are further treated with ocular lubricants. Ocular lubricants can be applied prophylactically to reduce the risk of corneal events.
[0073] In some methods described herein, bemarituzumab can be provided in a drug product composition comprising or consisting essentially of an aqueous solution comprising 20 mg / mL bemarituzumab, L-histidine, sucrose, and polysorbate 20 at a pH of 6.0. For example, the solution can comprise, consist essentially of, or consist of 20 mg / mL bemarituzumab, 20 mM L-histidine, 270 nM sucrose, and 0.01% (w / v) polysorbate 20 at a pH of 6.0.
[0074] Anti-FGFR2b antibodies (such as bemarituzumab) can be administered intravenously in the methods described herein.
[0075] CAPOX
[0076] CAPOX (also known as XELOX) is a chemotherapy regimen that includes capecitabine and oxaliplatin and is indicated for the treatment of advanced colorectal cancer. The most common side effects (≥30%) of capecitabine include diarrhea, hand-foot syndrome, nausea, vomiting, abdominal pain, fatigue / weakness, and hyperbilirubinemia. Other adverse reactions (including serious adverse reactions) have been reported (capecitabine Prescribing Information, 2021). The most common adverse reactions (≥40%) with oxaliplatin include peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, elevated transaminases and alkaline phosphatase, diarrhea, vomiting, fatigue, and stomatitis.
[0077] Oxaliplatin may be administered intravenously and capecitabine may be administered orally in the methods described herein.
[0078] SOX
[0079] SOX is a chemotherapy regimen that includes tegafur / gimeracil / oteracil (S-1) and oxaliplatin. S-1 combines tegafur, 5-chloro-2,4-dihydroxypyridine and oxapatite potassium. Tegafur is a metabolically activated 5-FU prodrug, and 5-chloro-2,4-dihydropyridine (CDHP) and oxapatite potassium (Oxo) are modulators: CDHP inhibits 5-FU degradation, and Oxo inhibits its activation in the gastrointestinal (GI) tract by inhibiting its activation in mucosal cells (Shirasaka, 2008).
[0080] S-1 has been shown to be non-inferior to 5-FU monotherapy for previously untreated metastatic gastric cancer, and SOX has been shown to be comparable to S-1 and cisplatin with an improved safety profile (Boku et al., 2009; Yamada et al., 2014). The most common side effects of S-1 combined with oxaliplatin include (≥40%) leukopenia, neutropenia, anemia, thrombocytopenia, elevated AST and ALT, diarrhea, nausea, fatigue, and sensory neuropathy.
[0081] Oxaliplatin can be administered intravenously in the methods described herein, while S-1 can be administered orally.
[0082] PD-1 / PD-L1 Antibodies
[0083] In some embodiments, the disclosed method further comprises administering an anti-PD-1 or anti-PD-L1 antibody to the subject. The PD-1 / PD-L1 axis is associated with the suppression of T cell immune responses in cancer. Antagonists of this pathway have been clinically validated in many solid tumor indications. Monoclonal antibodies targeting the PD-1 pathway have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. Exemplary anti-PD-1 antibodies include, but are not limited to, nivolumab, pembrolizumab, or cemiplimab. Exemplary anti-PD-L1 antibodies include, but are not limited to, atezolizumab, avelumab, and durvalumab.
[0084] Nivolumab, a PD-1 antibody that blocks its interaction with PD-L1, has recently been approved in the United States in combination with fluoropyrimidine- and platinum-containing chemotherapy. ) is a fully human IgG4 (S228P) PD-1 immune checkpoint inhibitor antibody that selectively blocks interaction with PD-1 ligands (PD-L1 and PD-L2), thereby blocking downregulation of anti-tumor T cell function (U.S. Patent No. 8,008,449; Wang et al., 2014 Cancer Immunol Res. 2(9):846-56).
[0085] Treatments for stomach cancer
[0086] Methods comprising administering an anti-FGFR2b antibody
[0087] Described herein is a method for treating a subject's gastric cancer such as gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. These methods may include administering an anti-FGFR2b antibody to a subject Q3W at a dosage of at least 15 mg / kg. These methods may further include administering an additional dose of 5-15 mg / kg of an anti-FGFR2b antibody 7-10 days after the first Q3W administration of the anti-FGFR2b antibody. The additional dose may be referred to as an "intervention" dose. In some methods, the anti-FGFR2b antibody is administered to a subject Q3W at a dosage of greater than 15 mg / kg to no more than 22 mg / kg (e.g., 15-22 mg / kg). In some methods, the anti-FGFR2b antibody is administered to the subject at a dose of about 15 mg / kg, about 17 mg / kg, about 20 mg / kg, about 22 mg / kg, about 25 mg / kg, or about 30 mg / kg (including ranges between any two of the listed values, such as 15-17 mg / kg, 17-20 mg / kg, 17-22 mg / kg, 17-25 mg / kg, 20-22 mg / kg, 20-25 mg / kg, 22-25 mg / kg, 20-30 mg / kg, greater than 22 mg / kg to no more than 30 mg / kg, or greater than 22 mg / kg to no more than 25 mg / kg). In some methods, the anti-FGFR2b antibody is administered to the subject at a dose of 15 mg / kg, Q3W. According to some methods described herein, an additional dose or "intervention" dose can be 5-15mg / kg (for example, 10-15mg / kg), and can be used 7-10 days after the first Q3W anti-FGFR2b antibody is used. According to some methods described herein, an additional dose or "intervention" dose can be 6-9mg / kg, 7-8mg / kg, 9-13mg / kg or 10-12mg / kg, and can be used 7-10 days after the first Q3W anti-FGFR2b antibody is used. For example, an additional dose or "intervention" dose can be about 7mg / kg, about 7.5mg / kg, about 8mg / kg, about 9mg / kg, about 9.5mg / kg, about 10mg / kg, about 10.5mg / kg, about 11mg / kg, about 11.5mg / kg or about 12mg / kg after the first Q3W anti-FGFR2b antibody is used 7-10 days. For any of the methods described herein, the anti-FGFR2b antibody can be bemarituzumab.
[0088] According to some embodiments, a method of treating gastric cancer in a subject is Figure 1The method may include administering an anti-FGFR2b antibody to a subject Q3W at a dose of at least 15 mg / kg or at least about 20 mg / kg (e.g., 15-22 mg / kg, 15-20 mg / kg, 15-17 mg / kg, 17-20 mg / kg, 17-22 mg / kg, 17-25 mg / kg, 20-22 mg / kg, 20-25 mg / kg, 22-25 mg / kg, 25-30 mg / kg, 20-30 mg / kg, about 15 mg / kg, about 17 mg / kg, about 20 mg / kg, about 22 mg / kg, about 25 mg / kg, or about 30 mg / kg). The method may further include administering to the subject an additional dose of 5-15 mg / kg or 10-15 mg / kg (e.g., 8 mg / kg, 7-7.5 mg / kg, 7.5-8 mg / kg, 7.5-9 mg / kg or 7.5-10 mg / kg, 7-9 mg / kg, 7-10 mg / kg, 10-12 mg / kg, about 7 mg / kg, about 7.5 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg or about 11 mg / kg) of the anti-FGFR2b antibody 7-10 days after the first administration of the anti-FGFR2b antibody.
[0089] In some embodiments, the method may include administering an anti-FGFR2b antibody to a subject Q3W at a dose of about 15 mg / kg, followed by administering an additional dose of about 7.5 mg / kg of anti-FGFR2b antibody 7-10 days after the first administration of the anti-FGFR2b antibody. For example, the method may include administering an anti-FGFR2b antibody to a subject Q3W at a dose of about 15 mg / kg, followed by administering an additional dose of about 7.5 mg / kg of anti-FGFR2b antibody 8 days after the first administration of the anti-FGFR2b antibody. In other embodiments, the method may include administering an anti-FGFR2b antibody to a subject Q3W at a dose of about 22 mg / kg, followed by administering an additional dose of about 11 mg / kg of anti-FGFR2b antibody 7-10 days after the first administration of the anti-FGFR2b antibody. For example, the method may comprise administering an anti-FGFR2b antibody to the subject Q3W at a dose of about 22 mg / kg, followed by an additional dose of the anti-FGFR2b antibody of about 11 mg / kg 8 days after the first administration of the anti-FGFR2b antibody.
[0090] Methods comprising administering an anti-FGFR2b antibody and CAPOX (oxaliplatin and capecitabine) or SOX (oxaliplatin and S-1)
[0091] In some embodiments, the methods described herein may further include administering oxaliplatin and capecitabine (CAPOX) to the subject. In other embodiments, the methods may further include administering oxaliplatin and S-1 (SOX). For any method described herein, the anti-FGFR2b antibody may be bemarituzumab.
[0092] According to some embodiments, a method of treating gastric cancer in a subject is Figure 1 The method may include administering an anti-FGFR2b antibody to the subject for the first time at a dose of at least 15 mg / kg (e.g., at least 20 mg / kg, at least 22 mg / kg, 25 mg / kg, 20-25 mg / kg, 20-30 mg / kg, or 25-30 mg / kg). The anti-FGFR2b antibody may be administered intravenously. The method may further include administering CAPOX to the subject Q3W, for example, at a dose of at least 65 mg / m 2 Q3W (eg, 65 mg / m 2 -150mg / m 2 Oxaliplatin is administered intravenously at a dose of at least 500 mg / m 2 (For example, 500 mg / m 2 -1500mg / m 2 Capecitabine may be administered orally twice a day at a dose of about 100-150 mg / m 2 (e.g., 100-120 mg / m 2 120-130mg / m 2 130-140mg / m 2 or 140-150 mg / m 2 ) is administered intravenously Q3W, and capecitabine may be about 750-1500 mg / m 2 (e.g., 750-800 mg / m 2 , 800-900mg / m 2 , 900-1000mg / m 2 1000-1100mg / m 2 1100-1200mg / m 2 1200-1300mg / m 2 1300-1400mg / m 2 or 1400-1500 mg / m 2) is orally administered twice a day at a dose of 5-15 mg / kg or 10-15 mg / kg (e.g., 8 mg / kg, 7-7.5 mg / kg, 7.5-8 mg / kg, 7.5-9 mg / kg, 7.5-10 mg / kg, 7-9 mg / kg, 7-10 mg / kg, 10-12 mg / kg, about 7 mg / kg, about 7.5 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, or about 11 mg / kg) to the subject 7-10 days after the first administration of the anti-FGFR2b antibody. For example, the method may comprise administering an anti-FGFR2b antibody intravenously at a dose of 15-22 mg / kg Q3W, administering an additional dose of 7-12 mg / kg of the anti-FGFR2b antibody 7-10 days after the first Q3W administration of the anti-FGFR2b antibody, and administering an additional dose of 100-150 mg / kg of the anti-FGFR2b antibody Q3W. 2 (such as 130mg / m 2 Oxaliplatin was administered intravenously at a dose of 750-1500 mg / m 2 (such as 1000mg / m 2 ) twice a day orally administering capecitabine at a dose of 22-30 mg / kg Q3W intravenously. In some embodiments, the method may comprise administering an anti-FGFR2b antibody at a dose of 22-30 mg / kg Q3W, and administering an additional dose of the anti-FGFR2b antibody of 10-12 mg / kg 7-10 days after the first Q3W administration of the anti-FGFR2b antibody, and administering an additional dose of the anti-FGFR2b antibody of 130 mg / kg Q3W intravenously. 2 Oxaliplatin was administered intravenously at a dose of 1000 mg / m 2 Capecitabine is administered orally twice a day at a dose of . Optionally, oxaliplatin and anti-FGFR2b antibodies can be administered simultaneously, for example, in a single composition or in separate compositions Q3W. For example, the anti-FGFR2b antibody can be bemarituzumab.
[0093] In other embodiments, the method of treating gastric cancer may include administering an anti-FGFR2b antibody to the subject for the first time at a dose of at least 15 mg / kg (e.g., at least 20 mg / kg, at least 22 mg / kg, 25 mg / kg, 20-25 mg / kg, 20-30 mg / kg, or 25-30 mg / kg). The anti-FGFR2b antibody may be administered intravenously. The method may further include administering SOX to the subject Q3W, for example, at a dose of at least 65 mg / m 2 Q3W (eg, 65 mg / m 2 -150 mg / m 2 Oxaliplatin was administered intravenously at a dose of at least 20 mg / m 2(e.g., 20 mg / m 2 -60 mg / m 2 ) twice a day. For example, oxaliplatin can be administered orally at about 100-150 mg / m 2 (e.g., 100-120 mg / m 2 , 120-130mg / m2, 130-140mg / m 2 or 140-150 mg / m 2 ) is administered intravenously at a dose of about 30-60 mg / m 2 (e.g., 30 mg / m 2 , 35mg / m 2 , 40mg / m 2 , 45mg / m 2 , 50mg / m 2 , 55mg / m 2 , 60mg / m 2 , or a range defined by any two of the foregoing values) is administered orally twice a day. Optionally, the method may further include administering to the subject an additional dose of 5-15 mg / kg or 10-15 mg / kg (e.g., 8 mg / kg, 7-7.5 mg / kg, 7.5-8 mg / kg, 7.5-9 mg / kg, 7.5-10 mg / kg, 7-9 mg / kg, 7-10 mg / kg, 10-12 mg / kg, about 7 mg / kg, about 7.5 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, or about 11 mg / kg) of anti-FGFR2b antibody 7-10 days after the first administration of the anti-FGFR2b antibody. For example, the method may comprise administering an anti-FGFR2b antibody intravenously at a dose of 15-22 mg / kg Q3W, administering an additional dose of 7-12 mg / kg 7-10 days after the first Q3W administration of the anti-FGFR2b antibody, and administering an additional dose of 10-150 mg / kg Q3W. 2 (such as 130mg / m 2 ) was administered intravenously Q3W, and oxaliplatin was administered at a dose of 30-60 mg / m 2 (such as 40mg / m 2 ) twice a day. In some embodiments, the method may comprise administering the anti-FGFR2b antibody intravenously at a dose of 22-30 mg / kg Q3W, administering an additional dose of 10-12 mg / kg 7-10 days after the first Q3W administration of the anti-FGFR2b antibody, and administering 130 mg / kg intravenously Q3W. 2 Oxaliplatin was administered intravenously at a dose of 40 mg / m 2S-1 is administered orally twice a day at a dose of . Optionally, oxaliplatin and anti-FGFR2b antibodies can be administered simultaneously, for example, in a single composition or in separate compositions Q3W. For example, the anti-FGFR2b antibody can be bemarituzumab.
[0094] Methods comprising administering anti-FGFR2b antibodies, CAPOX or SOX, and anti-PD-1 or anti-PD-L1 antibodies
[0095] like Figure 1 As depicted, the method for treating gastric cancer described herein may include administering an anti-FGFR2b antibody, CAPOX or SOX, and optionally an anti-PD-1 or anti-PD-L1 antibody to a subject. The anti-PD-1 antibody or anti-PD-L1 antibody may be any such antibody known in the art or disclosed herein. In some embodiments, the method includes administering an anti-PD-1 antibody. The anti-PD-1 antibody may be nivolumab. For example, the method for treating gastric cancer may include administering an anti-FGFR2b antibody, a chemotherapy regimen, and nivolumab to a subject, the chemotherapy regimen comprising: (a) oxaliplatin and capecitabine (CAPOX) or (b) oxaliplatin and S-1 (SOX) and nivolumab. In some embodiments, the method may include administering an anti-FGFR2b antibody Q3W at a dose of at least 15 mg / kg, administering an additional dose of 5-15 mg / kg of anti-FGFR2b antibody 7-10 days after the first Q3W administration of the anti-FGFR2b antibody, and administering at least 65 mg / m 2 Oxaliplatin is administered intravenously every 3 weeks at a dose of at least 500 mg / m 2 Capecitabine is administered orally twice a day at a dose of at least 20 mg / kg, and the anti-PD-1 antibody is administered Q3W. In other embodiments, the method may include administering the anti-FGFR2b antibody Q3W at a dose of at least 20 mg / kg, administering an additional dose of 10-15 mg / kg of the anti-FGFR2b antibody 7-10 days after the first Q3W administration of the anti-FGFR2b antibody, and administering at least 65 mg / kg Q3W. 2 Oxaliplatin is administered intravenously every 3 weeks at a dose of at least 500 mg / m 2 Capecitabine is administered orally twice a day at a dose of at least 15 mg / kg, and the anti-PD-1 antibody is administered Q3W. In some embodiments, the method may include administering the anti-FGFR2b antibody Q3W at a dose of at least 15 mg / kg, administering an additional dose of 5-15 mg / kg of the anti-FGFR2b antibody 7-10 days after the first Q3W administration of the anti-FGFR2b antibody, and administering at least 65 mg / kg Q3W. 2 Oxaliplatin is administered intravenously every 3 weeks at a dose of at least 20 mg / m 2S-1 is administered orally twice a day at a dose of at least 20 mg / kg, and the anti-PD-1 antibody is administered Q3W. In other embodiments, the method may include administering the anti-FGFR2b antibody Q3W at a dose of at least 20 mg / kg, administering an additional dose of 10-15 mg / kg of the anti-FGFR2b antibody 7-10 days after the first Q3W administration of the anti-FGFR2b antibody, and administering at least 65 mg / kg Q3W. 2 Oxaliplatin is administered intravenously every 3 weeks at a dose of at least 20 mg / m 2 S-1 was administered orally twice a day at a dose of , and the anti-PD-1 antibody was administered Q3W.
[0096] For any method of treating gastric cancer described herein, anti-PD-1 or anti-PD-L1 antibodies may be administered intravenously in a Q3W regimen comprising any suitable dose. For example, an anti-PD-1 antibody (such as nivolumab) may be administered at a dose of about 240mg-480mg (e.g., 250mg, 300mg, 400mg, or 450mg). In some embodiments, the method includes administering nivolumab at a dose of at least 300mg Q3W, such as a dose of 300-400mg Q3W (e.g., 310mg, 320mg, 330mg, 340mg, 350mg, 360mg, 370mg, 380mg, or 390mg). For example, nivolumab may be administered at a dose of about 360mg Q3W.
[0097] Described in accordance with some embodiments of the method is a study evaluating the safety, tolerability and efficacy of bamarituzumab in combination with CAPOX or SOX chemotherapy, optionally further in combination with anti-PD-1 or anti-PD-L1 antibodies in previously untreated advanced gastric cancer or gastroesophageal junction cancer. The study may include dosing and scheduling of bamarituzumab and CAPOX or SOX and optionally nivolumab, as described in the examples.
[0098] For any method for treating gastric cancer as described herein, the cells of the gastric cancer of the subject may express FGFR2b. For example, the cells of the gastric cancer of the subject may overexpress FGFR2b protein, overexpress FGFR2b mRNA, or include FGFR2b gene amplification. In some methods, the cells of gastric cancer express FGFR2b protein, as determined by immunohistochemistry (IHC). For example, at least 5%, 10%, 15% or 20% of gastric cancer cells overexpress FGFR2b, as determined by IHC. For example, the cells of the gastric cancer of the subject may have 2+ or 3+ FGFR2b staining intensity. For example, at least 5% (for example, 5%, 10%, 15% or 20%) of gastric cancer cells may have 1+, 2+ or 3+ FGFR2b staining intensity. If the cells of the subject's gastric cancer may have a FGFR2b staining intensity of 2+ or 3+, or if at least 5% of the gastric cancer cells may have a FGFR2b staining intensity of 1+, 2+ or 3+, then the subject's gastric cancer may be considered to overexpress FGFR2b. In some methods, if any cell of gastric cancer has a FGFR2b staining intensity of 2+ or 3+, as determined by IHC, the subject is determined to overexpress FGFR2b. It is conceivable that subjects with gastric cancer that overexpresses FGFR2b may particularly benefit from treatments including administering anti-FGFR2b antibodies described herein (such as bemarituzumab). Optionally, the PD-L1 expression of cells of gastric cancer is also evaluated, for example, by IHC.
[0099] The following examples further illustrate the invention but, of course, should not be construed as limiting its scope in any way.
[0100] Example 1: Phase 1b study of bemarituzumab combined with other anticancer therapies in previously untreated advanced gastric or gastroesophageal junction cancer with FGFR2b overexpression
[0101] This example describes a Phase 1b, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of bemarituzumab in combination with other anticancer therapies in subjects with advanced gastric or gastroesophageal junction adenocarcinoma expressing FGFR2b who had not received prior treatment for unresectable or metastatic disease.
[0102] Tumor specimens from subjects demonstrating FGFR2b overexpression prior to entry into this study are required. Tumor specimens will be centrally assessed for fibroblast growth factor receptor 2b (FGFR2b) overexpression by immunohistochemistry (IHC) (archived or fresh biopsy within 6 months of signing the prescreening informed consent [ICF]).
[0103] The study includes a prescreening period for FGFR2b testing, a 28-day screening period, a treatment period, a safety follow-up (SFU) period, and a long-term follow-up (LTFU) period. Subjects will receive treatment until disease progression, unacceptable toxicity, subject request, or death (whichever comes first).
[0104] Subjects could continue nivolumab treatment beyond initial Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 disease progression (PD) as assessed by the investigator, as long as they met all of the following criteria: (1) investigator-assessed clinical benefit; (2) tolerability of study drug; and (3) stable Eastern Cooperative Oncology Group (ECOG) performance status.
[0105] Treatment beyond progression will not delay imminent intervention to prevent serious complications of disease progression (ie, central nervous system (CNS) metastases).
[0106] Subjects who discontinue all study treatment for any reason other than withdrawal of consent will receive an SFU visit approximately 28 (+3) days after the last dose of study treatment. Additionally, subjects will receive long-term follow-up for survival (LTFU) approximately every 3 months (±1 month) for up to 2 years starting with the first dose of bemarituzumab.
[0107] Radiographic assessments will be performed by the investigator according to RECIST v1.1 and will be performed every 6 weeks (±7 days) until Week 56, and then every 12 weeks (±14 days). If a subject discontinues study treatment before radiographic disease progression, tumor assessments will continue until radiographic progression or initiation of additional anticancer therapy. The primary and secondary objectives and endpoints are summarized in Table 1 below, and the exploratory endpoints are summarized in Table 2.
[0108] Table 1
[0109]
[0110]
[0111] Table 2
[0112]
[0113]
[0114] This study is exploring the dosing of bemarituzumab in combination with other anticancer therapies. The following combinations are being evaluated:
[0115] Cohort A: Bemarituzumab and CAPOX
[0116] Cohort B: Bemarituzumab and SOX
[0117] Cohort C: bemarituzumab versus CAPOX and nivolumab
[0118] Cohort D: bemarituzumab with SOX and nivolumab.
[0119] Subjects will be enrolled in groups of 3 to 6 per dose level per cohort, and escalation will be guided primarily by safety responses to the different doses. Cohorts B and D will not enroll subjects in the United States (US) and are not within the scope of the US Food and Drug Administration Investigational New Drug Application. Cohorts A and B may begin simultaneously.
[0120] The dose levels of bemarituzumab are:
[0121] Dose Level 1: Bemarituzumab 15 mg / kg intravenously (IV) every 3 weeks (Q3W) and 7.5 mg / kg on Day 8 of Cycle 1 for 21 days; and
[0122] Dose Level 2: Bemarituzumab 22 mg / kg IV Q3W, 11 mg / kg on Day 8 of Cycle 1, for 21 days.
[0123] Once the Dose Level Review Team (DLRT) deems Dose Level 1 in Cohort A or B to be safe and tolerable, Dose Level 2 within the same combined cohort will be initiated.
[0124] Once the DLRT deems the dose level in Cohort A or B safe and tolerable, enrollment in Cohort C or D will begin to evaluate the safety and tolerability of the combination studied in Cohort A or B in combination with nivolumab.
[0125] For Cohorts C and D, if dose level 2 of bemarituzumab is evaluated as the starting dose, dose level 1 can be used as a de-escalated dose level for enrollment if the criteria for dose de-escalation are met.
[0126] The ramp-up / down of each cohort was determined using the Bayesian optimal interval (BOIN) guideline with a target toxicity rate of 0.25. Alternative dose levels or dosing schedules of bemarituzumab may be explored based on emerging safety and PK data.
[0127] Number of subjects
[0128] Nine subjects will be enrolled in Cohorts A and B, respectively (3 subjects at dose level 1, then 6 subjects at dose level 2), and 6 subjects will be enrolled in Cohorts C and D, respectively, at dose levels selected from Cohorts A and B. Up to 10 additional subjects may be enrolled at a given dose level in a given cohort to further evaluate safety. Therefore, the minimum number of subjects studied is 30. If dose reduction occurs after the first 3 subjects have been enrolled in Cohorts C or D, 9 subjects will initially be enrolled in each of these cohorts instead of 6 (3 at a dose level selected from Cohorts A and B, and 6 at a dose level below that), bringing the study to a maximum of 96 subjects. The study may be amended later to include additional combined cohorts and / or subjects for further safety or efficacy evaluations.
[0129] Summary of Subject Eligibility Criteria
[0130] Subjects are ≥18 years of age with unresectable, locally advanced, or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with documented histological overexpression of FGFR2b (not amenable to curative therapy). Subjects must be candidates for combination therapy (e.g., CAPOX or SOX with or without nivolumab) for a given cohort, have evaluable disease (measurable or non-measurable) according to RECIST v1.1, and must not have received prior treatment for unresectable or metastatic disease. Subjects with positive HER2 status will be excluded.
[0131] Once consent is given to the study, subjects will provide a medical history and undergo screening safety tests to confirm that all eligibility requirements for the study are met.
[0132] treat
[0133] Bemarituzumab was administered as an approximately 30-minute (±10-minute) IV infusion via a peripheral vein or central venous catheter (21-day cycle). For the first dose level, 15 mg / kg of bemarituzumab was administered IV every 21 days on Day 1 (D1) of each cycle, with a single 7.5 mg / kg dose administered on Day 8 of Cycle 1. For the second dose level, 22 mg / kg of bemarituzumab was administered IV every 21 days on D1 of each cycle, with a single 11 mg / kg dose administered on Day 8 of Cycle 1.
[0134] For CAPOX (21-day cycles), oxaliplatin administration will begin on Day 1 of each cycle after completion of the bemaritumumab (Cohort A) or nivolumab (Cohort C) infusion. On Day 1, 130 mg / m2 IV over 120 minutes 2 Oxaliplatin 1000 mg / m2 orally twice daily on days 1 to 14 2Capecitabine (ie, 1000 mg / m in the morning 2 and 1000 mg / m at night 2 ).
[0135] For SOX (21-day cycles), oxaliplatin administration will begin on Day 1 of each cycle after completion of the bemaritumumab (Cohort B) or nivolumab (Cohort D) infusion. On Day 1, 130 mg / m2 IV over 120 minutes 2 Oxaliplatin 40 mg / m2 orally twice daily on days 1 to 14 2 S-1 (i.e., 40 mg / m in the morning 2 and 40 mg / m at night 2 ).
[0136] Following completion of the bemaritumumab infusion, nivolumab administration (21-day cycles) will begin on Day 1 of each cycle. On Day 1, 360 mg of nivolumab will be administered IV over 30 minutes (±10 minutes).
[0137] Rationale for bemarituzumab dosing
[0138] The recommended dose levels 1 and 2 in this study are 15 mg / kg IV Q3W with 1 additional 7.5 mg / kg dose on Day 8 of Cycle 1 and 22 mg / kg IV Q3W with 1 additional 11 mg / kg dose on Day 8 of Cycle 1, respectively. This study will use dosing every 3 weeks (Q3W) rather than every 2 weeks (Q2W) to be consistent with the CAPOX and SOX Q3W regimens. The selection of the target Q2W dose used to support the selection of the Q3W dose in this study is summarized below. The starting dose (dose level 1) recommended in this study is the target Q2W dose of bemarituzumab evaluated in FPA144-004 (which will continue to be evaluated in Phase 3 studies (20210096, 20210098), but with a reduced dosing frequency from Q2W to Q3W) (15 mg / kg Q2W with 1 additional 7.5 mg / kg dose on Day 8 of Cycle 1). Dose level 2 was selected as a proportional increase in the target Q2W dose to account for the increased Q3W dosing interval within the linear dose range. Dose level 2 was predicted to be consistent with the concentration observed at the end of the dosing interval at steady state (C 谷,ss ) and the area under the serum concentration versus time curve at steady state during dosing divided by the dosing interval of the target Q2W dose (C 平均,ss ) matches, and if the maximum observed concentration (C 最大) above the target Q2W dose, if safety permits, then this dose level is expected to be effective. In summary, based on the safety and efficacy data observed from the FPA144-004 study, the dose selected for dose level 2 is prepared to balance safety and efficacy.
[0139] The FPA144-004 study of 15 mg / kg of bemarituzumab administered Q2W in combination with mFOLFOX6 with 1 additional 7.5 mg / kg dose on Day 8 of Cycle 1 achieved pre-specified statistical significance in all three of its pre-specified efficacy endpoints, including ORR, PFS, and OS, in subjects with FGFR2b-positive, non-HER2-positive, previously untreated advanced gastric or gastroesophageal junction cancer. Population PK analysis using PK data from studies FPA144-001, FPA144-002, and FPA144-004 demonstrated that although baseline weight, baseline albumin, sex, and combination therapy were identified as statistically significant covariates for the PK of bemarituzumab, no covariates were expected to have a clinically meaningful effect on bemarituzumab exposure. In this population in combination with mFOLFOX6, no dose adjustment based on any of these factors was required. Exposure-response analysis showed that 15 mg / kg Q2W with 1 additional 7.5 mg / kg dose on Day 8 of Cycle 1 adequately balanced safety and efficacy. Therefore, 15 mg / kg every 2 weeks with 1 additional 7.5 mg / kg dose on Day 8 of Cycle 1 was selected as the target Q2W dose to continue testing in combination with mFOLFOX6 in the Phase 3 study.
[0140] Rationale for Capecitabine and Oxaliplatin (CAPOX) Dosing
[0141] Capecitabine will be administered at 1000 mg / m 2 Oral administration twice a day (i.e., 1000 mg / m in the morning 2 and 1000 mg / m at night 2 ) for 14 days, followed by a 1-week break. Capecitabine should be taken with food. Oxaliplatin will be given at 130 mg / m on day 1 of each cycle. 2 IV administration. This regimen is the standard of care and has been studied in patients with advanced gastric cancer and / or gastroesophageal junction cancer (Park et al., 2008; Kim et al., 2012; National Comprehensive Cancer Network, 2021).
[0142] Rationale for Oxaliplatin and S-1(SOX) Dosing
[0143] S-1 will be administered at 40 mg / m 2Oral administration twice a day (ie, 40 mg / m in the morning 2 and 40 mg / m at night 2 ) or dose-adjusted by body surface area (BSA) based on local standard of care for 14 days, followed by a 1-week rest. Oxaliplatin will be administered at 130 mg / m on Day 1 of each cycle. 2 IV administration. This regimen is the standard of care in Japan and has been studied in patients with advanced gastric cancer and / or gastroesophageal junction cancer (Boku et al., 2019; Kim et al., 2012).
[0144] Rationale for nivolumab dosing
[0145] Nivolumab will be administered at 360 mg IV Q3W. This is the approved dose of nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for subjects with metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
[0146] Statistical considerations
[0147] Sample size considerations
[0148] If the true DLT rate is 30% and 3 subjects are treated at a dose level in a given cohort, the probability of observing at least 1 DLT is 66%; this probability increases to 89% if 6 subjects are treated and exceeds 99% if 13 or more subjects are treated.
[0149] Mid-term DLRT review
[0150] For each cohort, the DLRT will be convened to review all available safety, tolerability, laboratory, and PK data after subjects in Cohorts 3 to 6 complete the 21-day DLT evaluation period during dose-finding and 21 days after the last subject is enrolled in the dose cohort.
[0151] Preliminary and final analysis
[0152] The primary analysis is planned to be performed after the last subject completes the SFU period. The final analysis is planned to be performed after all subjects have completed the study.
[0153] Analytical methods
[0154] Descriptive statistics for selected demographic, safety, PK, efficacy, and biomarker data were provided. Descriptive statistics for continuous data included mean, median, standard deviation, and range, while categorical data were summarized using frequency counts and percentages. Response rates were presented with 95% exact CIs. Time-to-event endpoints were summarized using the Kaplan-Meier method.
[0155] End of study
[0156] An individual subject was considered to have completed the study if he / she had completed the last visit as shown in the schedule in Table 3. The study end date was defined as the date on which the last subject was assessed or received an intervention in the study for evaluation (i.e., the last visit of the last subject) across all study centers, including any additional parts of the study (e.g., LTFU, antibody testing), if applicable.
[0157]
[0158]
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
[0165]
[0166]
[0167]
[0168]
[0169]
[0170]
[0171]
[0172]
[0173]
[0174] Study Group
[0175] The investigator will maintain a screening log for all potential study candidates, including limited information about the potential candidates (e.g., screening date). This log can be completed and updated via interactive response technology (IRT). Eligibility criteria are evaluated during screening. Appropriate written informed consent must be obtained prior to any study-specific activities / procedures. Prospective approval of protocol deviations (also known as protocol waivers or exemptions) for recruitment and inclusion criteria will not be provided.
[0176] Inclusion criteria
[0177] Subjects were eligible for inclusion in the study only if all of the following criteria applied:
[0178] · Subjects provided informed consent before any study-specific activities / procedures began.
[0179] ·Be ≥ 18 years old (or the legal age of majority in the country, whichever is higher) when signing the ICF.
[0180] Pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
[0181] Unresectable locally advanced or metastatic (not amenable to curative therapy) disease.
[0182] The tumor overexpressed FGFR2b as determined by centrally performed IHC testing.
[0183] Eastern Cooperative Oncology Group Performance Score (ECOG-PS) of 0 to 1.
[0184] Adequate organ function, defined as follows:
[0185] oAbsolute neutrophil count ≥ 1.5 x 10 9 / L
[0186] o Platelet count ≥ 100 x 10 9 / L
[0187] oHemoglobin ≥ 9 g / dL
[0188] AST and ALT <3x upper limit of normal [ULN] (or <5x ULN if liver is involved). Total bilirubin <1.5x ULN (or <2x ULN if liver is involved; unless patient has Gilbert's disease).
[0189] Calculated or measured creatinine clearance (CrCl) ≥ 50 mL / min using the formula of Cockcroft and Gault ([140 – age] × body weight [kg] / [72 × creatinine mg / dL]) (x 0.85 if female). Twenty-four-hour urine collection is not required but is permitted.
[0190] International normalized ratio (INR) or prothrombin time (PT) <1.5×ULN
[0191] Subjects were candidates for CAPOX (Cohorts A, C) or SOX (Cohorts B, D) and / or nivolumab (Cohorts C, D).
[0192] Ability to take medications orally.
[0193] Non-measurable disease or non-measurable but evaluable disease according to RECIST v1.1.
[0194] Exclusion criteria
[0195] If any of the following criteria applied, the subject was excluded from the study.
[0196] Related diseases
[0197] Untreated or symptomatic CNS metastases and leptomeningeal disease.
[0198] Subjects with asymptomatic CNS metastases are eligible if they have been clinically stable for at least 4 weeks and have not required intervention (including the use of corticosteroids).
[0199] Subjects with treated brain metastases are eligible if they meet the following criteria:
[0200] oComplete definitive therapy at least 2 weeks before the first planned dose of study treatment (stereotactic radiosurgery at least 7 days before the first planned dose of study treatment).
[0201] o For at least 7 days prior to the first dose of study treatment: any CNS disease is clinically stable, the subject is off steroids for the CNS disease (unless steroids are indicated for reasons unrelated to the CNS disease), and the subject is off or on a stable dose of anti-epileptic medication.
[0202] Other medical conditions
[0203] Known positive HER2 status (as defined by IHC test positive 3+ or IHC 2+ and positive fluorescence in situ hybridization [FISH])
[0204] Impaired cardiac function or clinically significant heart disease, including: unstable angina within 6 months before the first dose of study treatment, acute myocardial infarction <6 months before the first dose of study treatment, New York Heart Association (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as mean systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg despite optimal treatment, measured according to the European Society of Hypertension / European Society of Cardiology [ESH / ESC] 2013 guidelines), uncontrolled arrhythmias requiring antiarrhythmic therapy other than beta-blockers or digoxin, active coronary artery disease, or corrected QT interval (QTc) ≥470.
[0205] Peripheral sensory neuropathy of grade 2 or higher.
[0206] Active infection requiring systemic therapy or uncontrolled infection within 14 days prior to first dose of study treatment.
[0207] Known human immunodeficiency virus (HIV) infection with a CD4+ T cell (CD4+) count <350 cells / μL, hepatitis C infection (hepatitis C subjects who have achieved a sustained virologic response after antiviral therapy are allowed), or hepatitis B infection (subjects with hepatitis B surface antigen [SAg] or core antibodies who have achieved a sustained virologic response with antiviral therapy against hepatitis B are allowed).
[0208] History of interstitial lung disease.
[0209] Evidence or recent (within 6 months) history of corneal coloboma, corneal ulcer, keratitis, or keratoconus, history of corneal transplant, or other known corneal abnormalities that may increase the risk of developing a corneal ulcer. Recent (within 6 months) corneal surgery or ophthalmic laser treatment.
[0210] Any evidence of ongoing ophthalmologic abnormalities or symptoms that are acute (within 4 weeks) or actively progressing.
[0211] Unwilling to avoid contact lens use during study treatment.
[0212] Gastrointestinal (GI) tract disease that precludes oral medications, malabsorption syndrome, requirement for IV nutrition, uncontrolled inflammatory GI disease (eg, Crohn's disease, ulcerative colitis).
[0213] History of other malignancies within the past 2 years, except for the following:
[0214] Curative treatment of non-melanoma skin malignancies
[0215] Cervical cancer in situ
[0216] Curative treatment of uterine cancer stage I
[0217] Curatively treated ductal or lobular breast cancer in situ who have not received any systemic therapy
[0218] Localized prostate cancer that has been treated surgically with curative intent and is presumed cured
[0219] Queues C and D only:
[0220] · History of solid organ transplantation.
[0221] Active autoimmune disease requiring systemic therapy (except replacement therapy) within the past 2 years or any other disease requiring immunosuppressive therapy at the time of the study.
[0222] Prior / concomitant therapy
[0223] Prior treatment for metastatic or unresectable disease.
[0224] Prior adjuvant or neoadjuvant therapy for localized disease is allowed, provided it has been completed more than 6 months before the first dose of study treatment
[0225] Palliative radiation therapy is allowed if it is completed more than 14 days before the first dose of study treatment
[0226] All treatment-related toxicities were required to resolve to ≤ Grade 1 before the first dose of study treatment, with the exception of alopecia or toxicity considered irreversible (defined as present and stable for >21 days) that was not otherwise described in the exclusion criteria
[0227] Prior treatment with any selective inhibitor of the FGF-FGFR pathway.
[0228] Major surgical procedure within 28 days prior to the first dose of study treatment.
[0229] Minor surgery requiring local / epidural anesthesia must be completed more than 72 hours prior to the first dose of study treatment. In all cases, subjects must be adequately recovered and stable prior to treatment administration.
[0230] Use oral coumarin-derivative anticoagulants.
[0231] Cohorts B and D only: Recent (within the past 24 weeks) use of flucytosine, an antifungal medication.
[0232] Cohorts C and D only: Systemic medications or prednisone or equivalent at doses >10 mg / day of immunosuppressive agents must be discontinued for at least 2 weeks prior to the first dose of study drug. Short-term use of high-dose corticosteroids and / or continuous low-dose prednisone (<10 mg / day) is permitted. In addition, inhaled, intranasal, intraocular, and / or joint injections of corticosteroids are permitted. Subjects who experience severe, life-threatening, or recurrent (Grade 2 or higher) immune-mediated adverse events or infusion-related reactions, including those leading to permanent discontinuation while on treatment with immuno-oncology agents.
[0233] Prior / concurrent clinical research experience
[0234] Currently receiving treatment in another investigational device or drug study within 28 days of enrollment during this clinical study. Participation in other investigational procedures concurrently with this study is excluded.
[0235] Other Exclusions
[0236] Female subjects of childbearing potential were advised not to use protocol-specified contraceptive methods during treatment and for an additional 9 months after the last dose of regimen-required treatment.
[0237] Female subjects were breastfeeding or planned to breastfeed during the study period and up to 5 days after the last dose of regimen-mandated treatment.
[0238] Female subjects planned to become pregnant during the study period up to 9 months after the last dose of regimen-mandated treatment.
[0239] Female subjects of childbearing potential had a positive pregnancy test as assessed by a high-sensitivity urine or serum pregnancy test at Screening and within 72 hours prior to the first dose of study treatment.
[0240] Male subjects with female partners of reproductive potential are advised to abstain from sexual activity (abstain from heterosexual intercourse) or use contraception during treatment and for an additional 6 months after the last dose of regimen-mandated therapy.
[0241] Male subjects who were unwilling to give up sperm donation during treatment and for an additional 6 months after the last dose of protocol-mandated therapy.
[0242] Known allergy, hypersensitivity, or contraindications to components of the bemarituzumab formulation (including polysorbates) or to the platinum-containing drugs capecitabine (including subjects with complete dihydropyrimidine dehydrogenase [DPD] deficiency; Cohorts A, C), S-1 (including subjects with complete DPD deficiency; Cohorts B, D), or nivolumab (Cohorts C, D).
[0243] To the knowledge of the subject and the Investigator, the subject may not be able to complete all protocol-required study visits or procedures and / or comply with all required study procedures (e.g., clinical outcome assessments).
[0244] History or evidence of any other clinically significant disorder, condition, or disease (other than those outlined above) that, in the opinion of the Investigator or Amgen physician (if consulted), would pose a risk to the subject’s safety or interfere with study evaluations, procedures, or completion.
[0245] Bemarituzumab, CAPOX or SOX, and nivolumab
[0246] Information on bemarituzumab, CAPOX, SOX, and nivolumab in this study, including dosing and dosing instructions, is shown in Tables 4 and 5 below:
[0247] Table 4. Investigational product: bemarituzumab and its administration
[0248]
[0249]
[0250] eCRF = electronic case report form; IV = intravenous; Q3W = every 3 weeks
[0251] Table 5. Dosage formulation and administration of CAPOX, SOX, and nivolumab
[0252]
[0253]
[0254] eCRF = electronic case report form; BSA = body surface area; IV = intravenous
[0255] Dose level determination
[0256] The study will explore the dose of bemarituzumab in combination with other anticancer therapies. The DLT period of the study is 21 days after the first dose. For a given cohort, a DLRT meeting will be held once 3 to 6 subjects are enrolled at a certain dose level and receive 21 days of safety follow-up. The DLRT will evaluate all available safety, laboratory and PK and rules generated by BOIN design (Liu and Yuan, 2015; Yuan et al., 2016) to guide their dose finding recommendations. The DLRT may recommend escalation to the next planned dose level, continuation of the current dose level, decrement to a lower dose level, or termination of the cohort. The BOIN escalation / decrement guidelines for each cohort are derived with a target toxicity rate of 0.25. The decision on dose escalation will take into account all available safety data from all cohorts and include available data from outside the 21-day DLT window. After receiving the DLRT recommendation, the team will make a final decision and will send a written notification of the dose change decision to the investigator.
[0257] The DLRT will design guidelines for using each queue based on BOIN as follows:
[0258] Subjects in a given cohort were treated at dose level 1.
[0259] To allocate doses to subjects in the next cohort, the guidelines in Table 6 will be used, with the exception of the following situations:
[0260] “Elimination” means eliminating current and higher doses from the cohort to prevent treatment of any future subjects at those doses because they are too toxic.
[0261] When a dose is eliminated, taper to the next lower dose level. When the lowest dose is eliminated, stop the cohort for safety.
[0262] If no action (ie, escalation, decrementation, or elimination) is triggered, new subjects are treated at the current dose.
[0263] If the current dose is the lowest dose and the rules indicate dose reduction, new subjects are treated at the lowest dose unless the number of DLTs reaches the elimination boundary, at which point the trial is stopped for safety reasons.
[0264] If the current dose is the highest dose and the rule indicates dose escalation, treat the new patient at the highest dose.
[0265] Repeat step 2 until a minimum of 6 subjects and a maximum of 16 subjects are reached for the dose level of interest, and the decision based on Table 6 is to maintain the current dose.
[0266] Table 6. Dose escalation / decrease rules based on BOIN design
[0267]
[0268]
[0269] BOIN = Bayesian optimal interval; DLT = dose-limiting toxicity
[0270] Dose-limiting toxicity
[0271] Dose-limiting toxicity during the dose-finding period was defined as any of the following adverse events that the investigator considered to be related to the study drug:
[0272] Grade 4 neutropenia of any duration
[0273] Febrile neutropenia
[0274] Grade 4 thrombocytopenia
[0275] Grade 3 thrombocytopenia, ≥ Grade 2 bleeding or lasting > 7 days
[0276] Grade 4 anemia
[0277] Grade 5 toxicity (eg, death not due to disease progression)
[0278] Any grade 3 ophthalmic adverse event that does not resolve within 7 days
[0279] Any grade 4 ophthalmic adverse event
[0280] Any Level 4 laboratory value
[0281] Any Grade 4 vomiting or diarrhea
[0282] Grade 3 vomiting or Grade 3 diarrhea persisting for more than 3 days despite best medical support
[0283] Grade 3 nausea persisting for 3 or more days despite best medical support
[0284] Grade 3 fatigue lasting 1 week or longer
[0285] Any subject who meets Hy's Law case criteria (i.e., severe drug-induced liver injury [DILI]) will be considered a DLT. A Hy's Law case is defined as an AST or ALT value ≥ 3x ULN and a serum TBIL level > 2x ULN or an international normalized ratio (INR) > 1.5, with no signs of cholestasis and no other clear alternative causes to explain the observed liver-related laboratory abnormalities (see section 11.7 for further explanation of Hy's Law cases and management of liver function).
[0286] Any other adverse events of grade ≥ 3, except for the following:
[0287] DLT exemption: Asymptomatic grade 3 electrolyte abnormalities lasting < 72 hours, are clinically uncomplicated, and resolve spontaneously or respond to medical intervention.
[0288] DLT waivers: Other selected laboratory abnormalities that appear to be clinically irrelevant or not harmful to the subject (e.g., Grade 3 lymphopenia, Grade 3 hypoalbuminemia), and / or can be corrected with substitution or modification.
[0289] DLT exemption: transient (resolving to ≤ Grade 1 within 6 hours of onset) grade 3 infusion-related adverse events.
[0290] DLT exemption: Any grade 3 endocrinopathies adequately controlled by hormone replacement.
[0291] Subjects enrolled in dose-finding may be replaced if they are not evaluable for DLT (e.g., the subject does not receive the planned study treatment [at least 100% of the planned dose for IV agents and at least 80% of the planned dose for oral agents]) or discontinue study treatment before the completion of the DLT evaluation period for reasons other than experiencing a DLT. Replaced subjects may continue on the study at the discretion of the investigator and after discussion with the Medical Monitor.
[0292] If the adverse event is clearly attributable to any component of the combination regimen (based on its known safety profile) and is no more severe than expected, then the specific adverse event may be considered to be exempt from being a DLT.
[0293] Rules for dose modification, delay, suspension or restart, and permanent discontinuation of bemarituzumab
[0294] The dose of Bemmarituzumab may be withheld for Bemmarituzumab-related adverse events following the guidelines outlined in Table 7.1. The reason for dose delay of Bemmarituzumab will be recorded on each subject's CRF.
[0295] After Cycle 1, the bemarituzumab dose should be recalculated only if there is a >10% change in body weight relative to Cycle 1 Day 1 (C1D1) body weight. If the dose is recalculated due to a >10% change in body weight relative to C1D1, the body weight used for the recalculated dose should serve as the new baseline for dose recalculations for subsequent evaluations.
[0296] If the investigator is considering dose reductions or interruptions that are not within these guidelines, these will need to be discussed with the sponsor or designee. Cycles may be delayed to manage toxicity. Cycle delays of more than 21 days should be discussed with the Medical Monitor prior to restarting.
[0297] Corneal Events: Any subject who experiences a corneal event within 100 days of the last dose of bemarituzumab, regardless of whether it is considered related or unrelated to bemarituzumab, should be evaluated by an ophthalmologist. Any subject who reports eye pain or irritation or changes in vision should be evaluated by an ophthalmologist. Tables 7.1, 7.2, and 7.3 provide additional guidance.
[0298] Table 7.1 Guidelines for dose modifications of bemarituzumab for adverse events
[0299]
[0300]
[0301] Table 7.2 Guidelines for dose modification of bemarituzumab for adverse events
[0302]
[0303]
[0304]
[0305] Table 7.3 Bemarituzumab adverse event dose modification guidelines
[0306]
[0307]
[0308] CTCAE = Common Terminology Criteria for Adverse Events; IV = intravenous; N / A = not applicable; NSAID = nonsteroidal anti-inflammatory drug
[0309] a Ocular adverse events other than corneal toxicity should follow dose modifications for all other bemarituzumab-related adverse events.
[0310] Rules for dose modification, delay, interruption or restart, and permanent discontinuation of CAPOX
[0311] Oxaliplatin
[0312] Dose modifications of oxaliplatin were allowed according to institutional standards or local package inserts.
[0313] Neurotoxicity
[0314] For grade 2 peripheral sensory neuropathy (moderate paresthesia or dysphoria), or limitation of instrumental activities of daily living, oxaliplatin should be skipped. When toxicity resolves to ≤ grade 1, resume oxaliplatin at 75% of the initial dose. If oxaliplatin is skipped for 6 weeks (2 consecutive doses) due to neurotoxicity, discontinue oxaliplatin.
[0315] Kidney damage
[0316] For normal renal function or mild to moderate renal impairment (CrCl>50mL / min), the full dose of oxaliplatin can be administered. For severe renal impairment, the oxaliplatin dose should be reduced to 75% of the initial dose.
[0317] Hematotoxicity
[0318] For Grade 2 or 3 thrombocytopenia, oxaliplatin should be reduced to 75% of the initial dose. For Grade 4 thrombocytopenia, the dose should be reduced to 50% of the initial dose. For Grade 3 or 4 neutropenia or febrile neutropenia, the oxaliplatin dose should be reduced to 75% of the initial dose.
[0319] Allergic reactions
[0320] If a subject experiences a Grade 1 or 2 allergic reaction to oxaliplatin, premedication should be given according to institutional practice prior to further subsequent administration of study medication. If a Grade 1 or 2 allergic reaction persists into the next cycle, appropriate premedication should be escalated prior to administration of oxaliplatin according to institutional practice. Treatment with oxaliplatin should be discontinued for subjects who experience a Grade 3 or 4 allergic reaction.
[0321] Capecitabine
[0322] Dose modifications of capecitabine were permitted according to institutional standards or local package inserts.
[0323] General dose modification guidelines for capecitabine are presented in Table 8. Toxicity caused by capecitabine administration can be managed by symptomatic treatment, dose interruption, and adjustment of capecitabine dose. Once the dose is reduced, it should not be increased later. The only exception to this practice is in the case of nausea / vomiting. If grade 2 or higher nausea and / or vomiting occurs despite the use of appropriate antiemetic therapy, the next dose of chemotherapy should be reduced by 25%. Appropriate antiemetic therapy should include at least 2 forms of medication (e.g., 5HT-3 receptor antagonists, NK1 receptor antagonists). If tolerated, an increase back to 100% dose may be allowed at the discretion of the investigator. Chemotherapy cycles may be delayed to control toxicity. Cycle delays of more than 21 days should be discussed with the medical monitor before restarting treatment.
[0324] Capecitabine doses omitted due to toxicity will not be replaced or resumed; instead, subjects should resume their scheduled treatment cycles. Phenytoin and capecitabine present a risk of drug interactions. When co-administered with capecitabine, a reduction in the phenytoin dose may be necessary because phenytoin levels may be increased due to the inhibition of CYP2C9 by capecitabine, leading to increased toxic levels of phenytoin.
[0325] Dihydropyrimidine dehydrogenase deficiency, an enzyme deficiency, may first manifest as a severe, life-threatening reaction to a fluoropyrimidine. Evaluation for DPD deficiency should be considered if the following events occur after capecitabine administration: severe diarrhea, mucositis, neutropenia, or neurotoxicity.
[0326] Table 8. Recommended dose modifications of capecitabine
[0327]
[0328]
[0329] Source: XELODA U.S. Prescribing Information 2021
[0330] a Adverse events were assessed according to the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Common Toxicity Criteria (version 1.0) or the U.S. National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0).
[0331] SOX Dose Modification, Delay, Suspension or Restart, Permanent Discontinuation Rules
[0332] S-1
[0333] Dose modifications of S-1 were permitted based on institutional standards or local package inserts.
[0334] General dose modification guidelines for S-1 are presented in Table 9. Toxicity caused by S-1 administration can be managed by symptomatic treatment, dose interruptions, and adjustments in the S-1 dose. Once the dose is reduced, it should not be increased later. The only exception to this practice is in the case of nausea / vomiting. If ≥ Grade 2 nausea and / or vomiting occurs despite the use of antiemetic therapy, the next dose of chemotherapy should be reduced. If tolerated, an increase back to the standard dose may be allowed at the discretion of the investigator. If a shortened withdrawal period is therapeutically necessary, it should be implemented after confirmation that there are no drug-induced abnormalities in laboratory findings (hematology tests, liver and renal function tests) and no gastrointestinal symptoms (i.e., the drug is not problematic in terms of safety). A withdrawal period of at least 7 days must be provided. Cycle delays of more than 21 days should be discussed with the medical monitor before restarting treatment. S-1 doses omitted due to toxicity will not be replaced or resumed; instead, subjects should resume the planned treatment cycle.
[0335] There is a risk of drug interactions between phenytoin and S-1. When co-administered with S-1, the phenytoin dose may need to be reduced because phenytoin levels may be increased due to S-1 inhibition of CYP2C9, resulting in increased toxic levels of phenytoin.
[0336] Dihydropyrimidine dehydrogenase (DPD) deficiency, an enzyme deficiency, can first manifest as a severe, life-threatening reaction to a fluoropyrimidine. Evaluation for DPD deficiency should be considered if the following events occur after administration of S-1: severe diarrhea, mucositis, neutropenia, or neurotoxicity.
[0337] If oxaliplatin administration is discontinued for any reason prior to disease progression, S-1 may be continued until disease progression or unacceptable toxicity occurs. If S-1 is permanently discontinued, oxaliplatin must be discontinued. Table 9 shows the recommended dose modifications for S-1. Further details can be found in the regional prescribing information. Institutional dose reduction guidelines may also be applied.
[0338] Table 9. Recommended dose modifications for S-1
[0339]
[0340] BID = twice a day, N / A = not applicable
[0341] Source: TS-ONE Japanese Prescription Information 2021
[0342] Rules for dose modification, delay, suspension or restart, and permanent discontinuation of nivolumab
[0343] Dose reduction of nivolumab is not recommended. In general, nivolumab should be withheld for grade ≥3 immune-mediated adverse reactions and permanently discontinued for life-threatening (grade ≥4) immune-mediated adverse events, recurrent severe (grade 3) immune-mediated reactions requiring systemic immunosuppressive therapy, or failure to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks of starting steroids. Additional information is shown in Table 10. If nivolumab is discontinued due to toxicity, chemotherapy and bemarituzumab may be continued. If all components of chemotherapy are discontinued, nivolumab may be continued. If any component of nivolumab is delayed or suspended during the first 3 cycles, bemarituzumab should be continued as planned. If any component of nivolumab is delayed for up to 7 days after the first 3 cycles, bemarituzumab should also be delayed to coincide with nivolumab dosing. If any component of nivolumab is withheld for more than 7 days or discontinued after the first 3 cycles, bemarituzumab should be continued as scheduled.
[0344] The reason for discontinuation of nivolumab will be recorded on each subject's eCRF.
[0345] Table 10. Nivolumab dose modifications
[0346]
[0347]
[0348] Source: OPDIVO U.S. Prescribing Information 2021
[0349] ALT = alanine aminotransferase; AST = aspartate aminotransferase; DRESS = drug-induced rash with eosinophilia and systemic symptoms; SJS = Stevens-Johnson syndrome; TEN = toxic epidermal necrolysis; ULN = upper limit of normal
[0350] a Resume in subjects who fully or partially resolve (Grade 0 to 1) following corticosteroid taper. Permanently discontinue if there is no full or partial resolution within 12 weeks after the last dose or if prednisone (or equivalent) cannot be tapered to 10 mg daily or less within 12 weeks of initiating steroids.
[0351] b If AST and ALT are less than or equal to ULN at baseline, withhold or permanently discontinue OPDIVO based on recommendations for hepatitis without liver involvement. Other causes of hepatitis should be excluded before attributing abnormalities to nivolumab.
[0352] cDepending on clinical severity, consider withholding for Grade 2 endocrinopathies until symptoms improve with hormone replacement. Resume after acute symptoms resolve.
[0353] Treatment compliance
[0354] When subjects are dosed at the study center, they will receive bemarituzumab, oxaliplatin, and nivolumab (where applicable) directly from the investigator or designee under medical supervision. The date and time of each dose administered will be recorded in the source documents and documented in the eCRF.
[0355] Capecitabine and S-1 will be administered by subjects at home. Adherence will be assessed by direct questioning, review of diaries, and counting returned study medications. The following procedures will be used to ensure proper medication accountability. Medication accountability will be emphasized at the start-up meeting. Medication accountability will be monitored throughout the study. Each subject will be instructed to return all study medication packaging and unused materials to the study center at each visit. The study center will record all study medications dispensed to subjects and returned by subjects throughout the study. Study center personnel will return all unused study medications to all subjects. Each subject will be instructed to keep a study diary to record his / her proper intake of study medications.
[0356] A subject must take ≥80% to ≤100% of the intended dose to be considered compliant with the administration of capecitabine and S-1. Similarly, if the investigator judges that a subject intentionally or repeatedly takes less or more than the prescribed amount (i.e., <80% or >100%), he / she may be considered noncompliant. The possible discontinuation of a subject due to study drug noncompliance will be discussed between the investigator and the medical monitor before the final decision to discontinue a subject is made.
[0357] Prior and concomitant treatment
[0358] Previous treatment
[0359] All prior medications must be documented on the designated eCRF form. Prior therapies taken / used in the 3 months prior to enrollment will be collected.
[0360] For prior therapy for gastric or gastroesophageal junction cancer, collect therapy name, setting, dose, unit, frequency, start date, stop date, best response, and reason for discontinuation. For anticancer therapy consisting of multiple separate components, collect information for each component. For all other prior therapies, collect therapy name, indication, dose, unit, frequency, route, start date, and stop date.
[0361] Concomitant therapy
[0362] Throughout the study, the investigator may prescribe any concomitant medication or treatment deemed necessary to provide adequate supportive care.
[0363] To reduce the risk of corneal toxicity, prophylactic use of ocular lubricants and eyelid hygiene are recommended. Ocular lubricants (e.g., preservative-free artificial tears) should be self-applied 3 times daily throughout treatment and for 30 days after the last dose. They can be polyvinyl alcohol- or liquid polyol-based. If preservative-free is not feasible, formulations containing preservatives are permitted. Methylcellulose-based lubricants should not be used. Viscous lubricants that can cause haziness should be avoided.
[0364] Concomitant therapies will be collected from informed consent to the end of the SFU, with the exception of ophthalmic and anticancer therapies, which will be collected through the LTFU. For concomitant therapies, including vaccines, collect the name of therapy, indication, dose, unit, frequency, route, start date, and stop date.
[0365] For subsequent therapy for gastric or gastroesophageal junction cancer, the drug name, start date, and stop date were collected.
[0366] Discontinuation of study treatment and subject discontinuation / withdrawal
[0367] Subjects have the right to withdraw from the study product and / or other protocol-required therapies, protocol procedures, or the entire study at any time and for any reason without affecting their future medical care by the physician or institution.
[0368] The Investigator and / or Sponsor may decide to withdraw a subject from the investigational product, device, and / or other protocol-required therapy, protocol procedures, or the entire study at any time prior to completion of the study for the reasons listed below.
[0369] Discontinuation of Study Treatment
[0370] A subject (or legally authorized representative) may refuse to continue receiving investigational products and / or other protocol-required therapies and / or procedures at any time during the study but may continue to participate in the study. If this occurs, the investigator will discuss with the subject the appropriate process for discontinuing the investigational product or other protocol-required therapy and must discuss with the subject the possibility of continuing the schedule of activities in Table 3, including different follow-up options (e.g., in person, by phone / mail, through family / friends, correspondence / communication with other treating physicians, review of medical records) and data collection (including endpoints, adverse events), and the decision must be documented in the subject's medical record. Subjects who discontinue investigational products and / or other protocol-required therapies and / or procedures should not automatically withdraw from the study. It is necessary for the subject to continue to participate in the study to ensure safety monitoring and / or collection of outcome data, as long as it is safe and feasible.
[0371] Reasons for premature withdrawal from one or more protocol-required evaluations of an investigational product or procedure may include any of the following:
[0372] ·Determined by the sponsor
[0373] Lost to follow-up
[0374] ·die
[0375] Adverse events
[0376] ·Subject requirements
[0377] · Determined not eligible
[0378] · Plan deviation
[0379] Disobedience
[0380] Disease progression
[0381] oRadiographic progression (RECIST v1.1)
[0382] oClinical progression (investigator's assessment)
[0383] Need for alternative treatments
[0384] ·Pregnancy.
[0385] Subject discontinuation / withdrawal from study
[0386] Withdrawal of consent for a study means that the subject does not wish to receive further protocol-required therapies or procedures, and the subject does not wish or cannot continue to participate in further research. The subject's data up to the time of withdrawal of consent will be included in the analysis of the study, and, where permitted, publicly available data after the withdrawal of consent may be included. The investigator will discuss with the subject the appropriate procedures for withdrawing from the study, and the subject's decision to withdraw must be documented in the subject's medical record. Subjects who withdraw from treatment or research or are removed from it will not be replaced. If a subject withdraws from a study, he or she may request that any specimens collected but not tested be destroyed.
[0387] Reasons for removing a subject from a study include:
[0388] ·Determined by the sponsor
[0389] Withdraw consent for research
[0390] ·die
[0391] Lost to follow-up.
[0392] Lost to follow-up
[0393] If a subject failed to return for multiple scheduled visits and the study center could not contact him or her, he or she was considered lost to follow-up.
[0394] If a subject fails to return to the clinic for a required study visit, the following actions must be taken:
[0395] The site must attempt to contact the subject and reschedule the missed visit as soon as possible, counsel the subject on the importance of maintaining the assigned visit schedule, and determine whether the subject wishes and / or is able to continue in the study.
[0396] In the event that a subject is considered lost to follow-up, the investigator or designee must make every effort to re-establish contact with the subject (three telephone calls where possible and, if necessary, a certified letter to the subject's last known mailing address, or local equivalent). These attempts at contact will be documented in the subject's medical record.
[0397] If the subject still could not be contacted, he / she would be considered withdrawn from the study, with the main reason being loss to follow-up.
[0398] For subjects lost to follow-up, researchers should search publicly available records to determine vital status, where permitted. This ensures that the resulting data set is as comprehensive as possible.
[0399] Efficacy Assessment and Procedures
[0400] Radiographic imaging evaluation
[0401] The extent of the disease will be evaluated by contrast-enhanced computed tomography (CT) / magnetic resonance imaging (MRI) according to RECIST v1.1. To reduce the radiation exposure of the subjects, low-dose CT should be used whenever possible.
[0402] Screening Scan:
[0403] The screening scan should be performed within 28 days prior to Cycle 1 Day 1 (the scan may be performed up to 31 days). If there are multiple screening scans, the one closest to enrollment will be used as the baseline.
[0404] Radiographic evaluation must include CT / MRI of the chest, abdomen, and pelvis, as well as evaluation of all other known disease sites according to institutional standards.
[0405] All subjects with brain metastases must undergo MRI of the brain. All brain scans for subjects with brain metastases are required to be MRI, unless MRI is contraindicated, in which case CT with contrast is acceptable. Brain imaging (MRI or CT) should be performed if signs or symptoms suggestive of CNS metastases are present.
[0406] Subsequent scans:
[0407] All subsequent scans should be performed in the same manner as the screening (e.g., with the same contrast, MRI field strength), preferably on the same scanner. If a change in imaging modality is necessary (e.g., unplanned assessment), consultation with the medical monitor is recommended.
[0408] During treatment and follow-up, radiographic imaging of the chest, abdomen, pelvis, and all other known disease sites will be performed independently of the treatment cycles as specified in the activity schedule (see Table 3). Imaging may be performed more frequently if clinically necessary at the discretion of the treating physician. Radiographic imaging and tumor assessments will be performed until the initiation of new anticancer therapy, disease progression, death, withdrawal of consent, or end of study, whichever occurs first. Disease response determinations for clinical management and response assessments will be performed at the clinical site according to RECIST v1.1.
[0409] Safety Assessment
[0410] The planned timing of all safety assessments is listed in Table 3 .
[0411] Vital signs
[0412] The following measurements must be taken: systolic / diastolic blood pressure, heart rate, respiratory rate, and body temperature. Subjects must be in a resting and calm state in a seated position for at least 5 minutes prior to blood pressure assessment. The position selected for the subject should be the same position used throughout the study and recorded on the Vital Signs eCRF. The position selected for the subject for temperature should be the same position used throughout the study and recorded on the Vital Signs eCRF.
[0413] Electrocardiogram (ECG)
[0414] The subject must be in a resting and calm state in the supine position for at least 5 minutes prior to the ECG assessment. If the subject is unable to be in the supine position, the subject should be in the most recumbent position possible. The ECG must include the following measurements: heart rate, QRS, QT, QTc, and PR interval. The principal investigator or designated site physician will review all ECGs. Once signed, the original ECG tracing will be retained with the subject's source file.
[0415] Clinical laboratory evaluation
[0416] The Investigator is responsible for reviewing laboratory test results and recording any clinically relevant changes that occur during the study in the event eCRF. The Investigator must determine whether an abnormal value for an individual study subject represents a clinically significant change from the subject's baseline value. In general, abnormal laboratory findings that are not clinically significant (based on the Investigator's judgment) will not be recorded as adverse events. However, changes in laboratory values that require treatment or adjustment of current therapy are considered adverse events. Where applicable, clinical sequelae (rather than laboratory abnormalities) will be recorded as adverse events.
[0417] All protocol-required laboratory assessments must be performed according to the activity plan (Table 3).
[0418] Life Status
[0419] The vital status of all subjects must be obtained within the limits of local law. This includes subjects who may have discontinued study visits with or without consent withdrawal and should include searching public databases if necessary. If deceased, the date of death and reported cause of death should be obtained.
[0420] Eye examination
[0421] Ophthalmologic examinations will be performed according to the activity schedule in Table 3. Ophthalmologic adverse events of any grade occurring up to 100 days after the last dose of bemarituzumab should be reported.
[0422] Ophthalmologic examination should include distance-corrected visual activity for each eye separately (where visual acuity is recorded as logMAR equivalent), slit-lamp examination of the anterior segment, ocular surface staining (e.g., fluorescein), dilated retinal examination, or 3-field retinal photographs. In addition, optical coherence tomography (OCT) of the macula is specifically indicated for subjects diagnosed with retinal pigment epithelial (RPE) detachment.
[0423] Ophthalmologic examinations should be performed according to the active schedule, regardless of dosing delays. Ophthalmologic examinations may be repeated at any time as clinically indicated. After the SFU visit, if a subject has any persistent ophthalmologic findings, assessments should continue until these findings resolve, consent is withdrawn, death, or loss to follow-up. Ophthalmologists should monitor for ocular adverse events until resolution.
[0424] The following actions will be implemented for ophthalmic adverse events:
[0425] Managed according to standards of care
[0426] Investigator guidance for dose modifications and interruptions is provided in Table 7.3.
[0427] Subjects should be evaluated if any clinically significant changes are noted compared to the previous examination or if they have any ocular signs or symptoms of Grade 2 or higher.
[0428] Adverse Events
[0429] The adverse event grading scale used for this study will be the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
[0430] The Investigator is responsible for ensuring that all Investigator-observed or subject-reported adverse events occurring after the first dose of study product / study treatment / protocol-required therapy until the end of the SFU visit are reported using the Event eCRF. Adverse events are expected to be recorded within 28 (+3) days after the last day of study product administration.
[0431] Serious adverse events
[0432] The investigator is responsible for ensuring that all serious adverse events observed by the investigator or reported by the subject occurring after informed consent until 28 (+3) days after the last day of administration of the study product are reported using the event eCRF. During the prescreening period, only serious adverse events related to the prescreening procedure will be collected. Serious adverse events suspected to be related to the study product should be recorded until the end of the study.
[0433] All serious adverse events will be collected, recorded and reported to the Sponsor or designee within 24 hours after the Investigator becomes aware of the event. The Investigator will submit any updated serious adverse event data to the Sponsor within 24 hours of its availability.
[0434] Because the criteria of the CTCAE grading scale differ from the regulatory criteria for serious adverse events, if an adverse event corresponds to a grade 4 CTCAE toxicity grading scale criteria (e.g., laboratory abnormalities reported as grade 4 but not presenting a life-threatening condition), it will be left to the investigator’s discretion whether to also report these abnormalities as serious adverse events. For any adverse event that applies in this context, comprehensive documentation of the severity of the event must be recorded in the subject’s medical record.
[0435] If the investigator becomes aware of a serious adverse event suspected to be related to the investigational product or any fatal adverse event (regardless of causality) after the end of the protocol-required reporting period, these serious adverse events will be reported within 24 hours of the investigator becoming aware of the event.
[0436] Serious adverse events reported outside of the protocol-required reporting period will be captured in the safety database as clinical trial cases and handled accordingly based on their relationship to the investigational product.
[0437] If further safety-related data are needed to satisfy any regulatory reporting requirements for a reportable event, it may be necessary to collect additional information from the subject's records after the subject has left the study.
[0438] After the initial AE / SERV report, the investigator is required to actively follow up each subject at subsequent visits / contacts. All AEs and SERVs will be followed until resolved, stabilized, until the event has an alternative explanation, or the subject is lost to follow-up.
[0439] It is essential that investigators notify the sponsor of serious adverse events in a timely manner in order to fulfill their legal obligations and ethical responsibilities for the safety of subjects and the safety of study treatments in clinical studies.
[0440] Sponsors have a legal responsibility to inform local and other regulatory authorities about the safety of investigational treatments in clinical studies. Sponsors will comply with country-specific regulatory requirements related to reporting safety to regulatory authorities, IRBs / IECs, and investigators.
[0441] Individual safety reports must be prepared for suspected unexpected serious adverse reactions in accordance with local regulatory requirements and sponsor policy and forwarded to the investigator when necessary.
[0442] Investigators who receive individual safety reports describing serious adverse events or other specific safety information (e.g., summaries or tabulations of serious adverse events) from the sponsor will archive them with the Investigator's Brochure and will notify the IRB / IEC, as appropriate, in accordance with local requirements.
[0443] For studies that are blinded to treatment allocation, in order to comply with global serious adverse event reporting regulations, Amgen may unblind the treatment allocation of subjects with serious, unexpected and relevant adverse events before submission to regulatory agencies. The safety assessment team may also unblind the comprehensive analysis at its discretion. Investigators will receive notification of relevant serious adverse event reports sent to regulatory agencies in accordance with local requirements.
[0444] Adverse Events of Special Interest
[0445] Adverse events selected, referred to as bemarituzumab adverse events of special interest, are ocular adverse events of any grade or severity occurring up to 100 days after the last dose of bemarituzumab and should be collected as adverse events. Ocular adverse events, including corneal adverse events, should be graded using the ocular toxicity grading scale. Subjects should be assessed for possible bemarituzumab events of special interest prior to each dose.
[0446] Pregnancy and breastfeeding
[0447] Details of all pregnancies and / or breastfeeding will be collected and reported for female subjects and female partners of male subjects. Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, and ectopic pregnancy) are considered serious adverse events.
[0448] For females of childbearing potential, a high-sensitivity (serum) pregnancy test should be completed at Screening and within 72 hours of starting the investigational product. Females who have undergone bilateral tubal ligation / occlusion should undergo pregnancy testing as required by the protocol.
[0449] A high-sensitivity (urine or serum) pregnancy test should be performed each cycle until 28 (+3) days after discontinuation of protocol-required therapy. Additional on-treatment pregnancy testing may be performed at the investigator's discretion or as required by local laws and regulations.
[0450] Pharmacokinetic evaluation
[0451] Collect approximately 4 mL of whole blood samples for measurement of serum concentrations of bemarituzumab as specified in the activity schedule (Table 3). The actual sample collection date and time (24-hour clock time) will be recorded for each sample.
[0452] Pharmacogenetic assessment
[0453] If the subject consents to the optional pharmacogenetic portion of this study, DNA analysis may be performed. These optional pharmacogenetic analyses focus on inherited gene variations to evaluate their possible relevance to disease and / or responsiveness to the therapy used in this study. Goals of optional studies include using genetic markers to help study cancer and / or identify subjects who may respond positively or negatively to the investigational product. No additional samples were collected for this portion of the study. DNA may be extracted for subjects who consent to this / these analyses.
[0454] Antibody testing procedures
[0455] Blood samples for antibody testing will be collected at the time points specified in the activity schedule (Table 3) to measure anti-bemarituzumab antibodies. Samples that test positive for binding antibodies can be further characterized.
[0456] Subjects who test positive for antibodies at the final scheduled antibody time point and have clinical sequelae that are thought to be possibly related to an anti-bemarituzumab antibody response will also be asked to return for additional follow-up testing. This testing will be performed approximately every 3 months starting at the final scheduled antibody time point and continuing until: (1) antibodies are no longer detectable; or (2) the subject has been followed for at least 1 year (±4 weeks) after administration of bemarituzumab. All follow-up results (positive and negative) will be communicated to the study center. If safety-related concerns arise, more frequent testing or testing for longer periods of time may be requested.
[0457] Biomarkers
[0458] Biomarkers are objectively measured and evaluated indicators of normal biological processes, pathogenic processes, or pharmacological responses to therapeutic interventions.
[0459] Biomarker Assessment to Determine Eligibility
[0460] Prescreening FGFR2b overexpression testing by IHC requires the provision of an archived tumor biopsy / excision or fresh biopsy fixed in formalin and embedded in paraffin. Fine needle aspirates, bone biopsies, and cytology specimens are inappropriate specimen types. Collection of primary tumor and metastatic site specimens is permitted. Enrollment requires fibroblast growth factor receptor 2b (FGFR2b) positive overexpression status, and subjects must consent to tumor tissue analysis. If collection of fresh tissue samples is required, these should be obtained in accordance with local standards of care procedures, and these procedures are not expected to pose any additional significant risks to the health, safety, and well-being of the subjects.
[0461] Subjects were selected for enrollment based on FGFR2b overexpression, as determined by the in vitro diagnostic (IVD) IHC assay of a central laboratory. The in vitro diagnostic (IVD) IHC assay used to select subjects was VENTANA FGFR2b (FPR2-D) assay, an IHC test for detecting FGFR2b protein in neoplastic tissue. Subject tissues must be evaluated according to the VENTANA FGFR2b (FPR2-D) assay scoring algorithm to determine FGFR2b status. The time for sample collection is described in the activity schedule (Table 3).
[0462] Subjects who do not demonstrate FGFR2b overexpression using IHC will not be eligible for enrollment. Specimens that demonstrate any heavy to strong membranous staining will yield FGFR2b overexpression. It is the responsibility of each investigator to obtain appropriate tumor specimens to be analyzed for FGFR2b positivity for enrollment. Standard of care biopsy specimens may be used if the specimen is obtained within 6 months prior to prescreening or a fresh biopsy. Blocks (if available) are preferred, but in lieu of blocks, unstained slides are recommended. The amount of tumor specimen submitted should be sufficient for IHC analysis; see the laboratory manual for details. Instructions for handling, labeling, and shipping of tumor slide or tumor block specimens are detailed in the laboratory manual that will be distributed with the specimen collection kit.
[0463] Once tumor specimens are received, they will be analyzed as efficiently as possible and the results of FGFR2b overexpression status will be fed back to the investigator or designee.
[0464] Biomarker Assessment During the Study
[0465] PD-L1 testing will be performed on remaining archived pre-treatment tissue (if available) in the indications listed in the activity schedule in Table 3.
[0466] Biomarker Discovery
[0467] Samples will be collected for exploratory biomarker analysis with the goal of understanding the drug's mechanism of action, assessing the amount of tumor growth, or predicting disease progression and response to the investigational product or protocol-required therapy. These samples may also be used to develop methods to better understand the disease. Tests may be designed to identify subjects most likely to respond positively or negatively to bemarituzumab or protocol-required therapy to study and further understand gastric cancer.
[0468] Blood and tissue will be collected for biomarker development at time points specified in the activity schedule (Table 3) if permitted by local regulations and approved by the ethics committee (EC) / institutional review board (IRB). Blood samples will be collected for evaluation of circulating tumor / cell-free DNA mutation profiles for potential associations with clinical endpoints. Circulating tumor / cell-free DNA will be evaluated for analysis of somatic mutations. Tumor samples will be used to examine protein expression, including FGFR2b, PD-L1, and other potential biomarkers that may include RNA or DNA gene expression or somatic (tumor) mutation analysis.
[0469] Statistical considerations
[0470] Statistical assumptions
[0471] No statistical hypotheses will be tested.
[0472] Sample size determination
[0473] If the true DLT rate is 30% and 3 subjects are treated at a dose level in a given cohort, the probability of observing at least 1 DLT is 66%; this probability increases to 89% if 6 subjects are treated and exceeds 99% if 13 or more subjects are treated.
[0474] Analyze groups
[0475] The following groups are defined in Table 11:
[0476] Table 11
[0477]
[0478] Covariates
[0479] The relationship between covariates and endpoints can be explored and specified in the statistical analysis plan (if appropriate).
[0480] Subgroup
[0481] If appropriate, subgroups can be explored and specified in the statistical analysis plan.
[0482] Statistical analysis
[0483] The statistical analysis plan will be developed and finalized before the database is locked. The following is a summary of the timing and methods of the planned statistical analysis.
[0484] Plan Analysis
[0485] Interim Analysis and Early Stopping Guidelines
[0486] During the DLRM, all available cumulative data (safety, tolerability, laboratory, PK, and efficacy) will be reviewed by cohort before dose escalation or dose reduction recommendations are made. Adverse events and DLTs observed in all subjects will be continuously evaluated and fully integrated into all DLRMs and considered in all enrollment and dosing decisions. DLRMs occur during the dose-finding period and 21 days after the last subject is enrolled in a dose cohort.
[0487] Guidelines for dose escalation or de-escalation to the next dose level were determined by using a BOIN design (see Table 6).
[0488] The primary analysis is planned to be performed after all subjects have completed the SFU period. The final analysis is planned to be performed after all subjects have ended the study.
[0489] Analytical methods
[0490] Data will be summarized by cohort and dose level. Descriptive statistics for continuous data will include mean, median, standard deviation, and range, while categorical data will be summarized using frequency counts and percentages. Unless otherwise specified, data will be summarized using the safety analysis set.
[0491] Confidence intervals (CIs) for proportions will be estimated using the exact method proposed by Clopper-Pearson (Clopper and Pearson, 1934). The Kaplan-Meier (KM) method will be used to estimate medians and percentiles of time to event endpoints, with CIs calculated using the Brookmeyer and Crowley method (Brookmeyer and Crowley, 1982). The Kaplan-Meier method will be used to estimate landmarks of time to event endpoints (e.g., 1-year OS), with the Greenwood formula (Kalbfleisch and Prentice, 1980) used to estimate standard errors in the CI calculations.
[0492] Efficacy analysis
[0493]
[0494]
[0495] Security Analysis
[0496]
[0497] Adverse Events
[0498] Subject incidence rates for all treatment-emergent adverse events will be tabulated by system organ class and preferred term. Tabulations of grade ≥3 events, fatal adverse events, serious adverse events, adverse events leading to study product discontinuation / withdrawal, and adverse events of interest will also be provided.
[0499] Laboratory test results
[0500] Analyses of safety laboratory endpoints will include summary statistics and shifts in the grade of safety laboratory values between baseline and worst study value.
[0501] Vital signs
[0502] Analysis of vital signs will include summary statistics and shifts in vital sign values between baseline and worst study values.
[0503] Physical Measurement
[0504] Analysis of physical measurements will include summary statistics.
[0505] Electrocardiogram
[0506] ECG measurements in this clinical study were performed according to the standard of care for routine safety monitoring and not to assess potential QTc effects. Because these evaluations may not necessarily be performed under the rigorous conditions expected for a meaningful evaluation of QTc data; no summary and statistical analysis of the ECG measurements were planned, and these data would not be expected to be useful for meta-analysis of data from other trials.
[0507] Antibody formation
[0508] The incidence and percentage of subjects who developed anti-bemarituzumab antibodies at any time will be tabulated by treatment group.
[0509] Exposure to investigational products
[0510] Descriptive statistics will be used to summarize the number of days of study product use, total dose of study product, and dose intensity.
[0511] Exposure to non-study product
[0512] The number of days of non-study product use, total dose of non-study product, and dose intensity will be summarized using descriptive statistics.
[0513] Exposure to concomitant medications
[0514] The number and proportion of subjects receiving the treatment of interest will be summarized by the preferred term for each treatment group coded by the World Health Organization Drug Dictionary.
[0515] Other analyses
[0516] The pharmacokinetic parameters of bemarituzumab will be determined, including but not limited to AUC, C 最大 , C 谷 PK data collected from this study will be combined with PK data collected from other bemarituzumab studies for population PK analysis. Additional analyses will be performed to evaluate the relationship between bemarituzumab exposure and selected safety or efficacy or any relevant biomarker endpoints (if data are available). The details and results of these exploratory analyses will be described in a separate report.
[0517] Example 2: Treatment of patients with gastric cancer with bemarituzumab and CAPOX
[0518] A group of patients with pathologically confirmed locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with FGFR2b overexpression were treated with bemarituzumab at one of the following doses:
[0519] (1) a dose of 15 mg / kg administered intravenously on Day 1 (D1) of Cycle 1 and Q3W thereafter, and a single dose of 7.5 mg / kg administered on Day 8 of Cycle 1; or
[0520] (2) A dose of 22 mg / kg was administered intravenously on D1 of Cycle 1 and Q3W thereafter, and a single dose of 11 mg / kg was administered on Day 8 of Cycle 1.
[0521] In addition, these patients were treated with CAPOX after the completion of the bemaritumumab infusion. Specifically, oxaliplatin was administered at 130 mg / m on day 1 of each cycle. 2 The dose is given intravenously over 120 minutes. On days 1 to 14 of each cycle, 1000 mg / m 2 Capecitabine was administered orally twice daily (i.e., 1000 mg / m in the morning). 2and 1000 mg / m at night 2 ).
[0522] The combination of bemarituzumab and CAPOX is effective in treating gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in these patients, as measured by an objective response (defined as complete response (CR) + partial response (PR) as determined according to Response Evaluation Criteria in Solid Tumors [RECIST v1.1]).
[0523] Example 3: Treatment of gastric cancer patients with bemarituzumab and SOX
[0524] A group of patients with pathologically confirmed locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with FGFR2b overexpression were treated with bemarituzumab at one of the following doses:
[0525] (1) a dose of 15 mg / kg administered intravenously on Day 1 (D1) of Cycle 1 and Q3W thereafter, and a single dose of 7.5 mg / kg administered on Day 8 of Cycle 1; or
[0526] (2) A dose of 22 mg / kg was administered intravenously on D1 of Cycle 1 and Q3W thereafter, and a single dose of 11 mg / kg was administered on Day 8 of Cycle 1.
[0527] In addition, these patients were treated with SOX after the completion of the bemaritumumab infusion. Specifically, oxaliplatin was administered on day 1 of each cycle at 130 mg / m 2 The dose is given intravenously over 120 minutes. On days 1 to 14 of each cycle, 40 mg / m 2 The dose of S-1 was administered orally twice daily (i.e., 40 mg / m in the morning). 2 and 40 mg / m at night 2 ).
[0528] The combination of bemarituzumab and SOX was effective in treating gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in these patients, as measured by an objective response (defined as complete response (CR) + partial response (PR) as determined according to Response Evaluation Criteria in Solid Tumors [RECIST v1.1]).
[0529] Example 4: Treatment of patients with gastric cancer with bemarituzumab and CAPOX
[0530] A group of patients with pathologically confirmed locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with FGFR2b overexpression were treated with bemarituzumab at one of the following doses:
[0531] (1) a dose of 15 mg / kg administered intravenously on Day 1 (D1) of Cycle 1 and Q3W thereafter, and a single dose of 7.5 mg / kg administered on Day 8 of Cycle 1; or
[0532] (2) A dose of 22 mg / kg was administered intravenously on D1 of Cycle 1 and Q3W thereafter, and a single dose of 11 mg / kg was administered on Day 8 of Cycle 1.
[0533] In addition, these patients were treated with CAPOX after the completion of the bemaritumumab infusion. Specifically, oxaliplatin was administered at 130 mg / m on day 1 of each cycle. 2 The dose is given intravenously over 120 minutes. On days 1 to 14 of each cycle, 1000 mg / m 2 Capecitabine was administered orally twice daily (i.e., 1000 mg / m in the morning). 2 and 1000 mg / m at night 2 ).
[0534] The combination of bemarituzumab and CAPOX is effective in treating gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in these patients, as measured by progression-free survival and / or overall survival.
[0535] Example 5: Treatment of gastric cancer patients with bemarituzumab and SOX
[0536] A group of patients with pathologically confirmed locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with FGFR2b overexpression were treated with bemarituzumab at one of the following doses:
[0537] (1) a dose of 15 mg / kg administered intravenously on Day 1 (D1) of Cycle 1 and Q3W thereafter, and a single dose of 7.5 mg / kg administered on Day 8 of Cycle 1; or
[0538] (2) A dose of 22 mg / kg was administered intravenously on D1 of Cycle 1 and Q3W thereafter, and a single dose of 11 mg / kg was administered on Day 8 of Cycle 1.
[0539] In addition, these patients were treated with SOX after the completion of the bemaritumumab infusion. Specifically, oxaliplatin was administered on day 1 of each cycle at 130 mg / m 2 The dose is given intravenously over 120 minutes. On days 1 to 14 of each cycle, 40 mg / m 2 The dose of S-1 was administered orally twice daily (i.e., 40 mg / m in the morning). 2 and 40 mg / m at night 2 ).
[0540] The combination of bemarituzumab and SOX is effective in treating gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in these patients as measured by progression-free survival and / or overall survival.
[0541] Example 6: Treatment of patients with gastric cancer with bemarituzumab, CAPOX, and nivolumab
[0542] A group of patients with pathologically confirmed locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with FGFR2b overexpression were treated with bemarituzumab at one of the following doses:
[0543] (1) a dose of 15 mg / kg administered intravenously on Day 1 (D1) of Cycle 1 and Q3W thereafter, and a single dose of 7.5 mg / kg administered on Day 8 of Cycle 1; or
[0544] (2) A dose of 22 mg / kg was administered intravenously on D1 of Cycle 1 and Q3W thereafter, and a single dose of 11 mg / kg was administered on Day 8 of Cycle 1.
[0545] These patients were also treated with nivolumab after the completion of the bemarituzumab infusion. Nivolumab was administered intravenously over 30 minutes (±10 minutes) on Day 1 of each cycle at a dose of 360 mg.
[0546] In addition, these patients were treated with CAPOX after the completion of the nivolumab infusion. Specifically, oxaliplatin was administered at 130 mg / m on day 1 of each cycle. 2 The dose is given intravenously over 120 minutes. On days 1 to 14 of each cycle, 1000 mg / m 2 Capecitabine was administered orally twice daily (i.e., 1000 mg / m in the morning). 2 and 1000 mg / m at night 2 ).
[0547] The combination of bemarituzumab, CAPOX, and nivolumab was effective in treating gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in these patients, as measured by an objective response (defined as complete response (CR) + partial response (PR) as determined according to Response Evaluation Criteria in Solid Tumors [RECIST v1.1]).
[0548] Example 7: Treatment of patients with gastric cancer with bemarituzumab, SOX, and nivolumab
[0549] A group of patients with pathologically confirmed locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with FGFR2b overexpression were treated with bemarituzumab at one of the following doses:
[0550] (1) a dose of 15 mg / kg administered intravenously on Day 1 (D1) of Cycle 1 and Q3W thereafter, and a single dose of 7.5 mg / kg administered on Day 8 of Cycle 1; or
[0551] (2) A dose of 22 mg / kg was administered intravenously on D1 of Cycle 1 and Q3W thereafter, and a single dose of 11 mg / kg was administered on Day 8 of Cycle 1.
[0552] These patients were also treated with nivolumab after the completion of the bemarituzumab infusion. Nivolumab was administered intravenously over 30 minutes (±10 minutes) on Day 1 of each cycle at a dose of 360 mg.
[0553] In addition, these patients were treated with SOX after the completion of the nivolumab infusion. Specifically, oxaliplatin was administered at 130 mg / m on day 1 of each cycle. 2 The dose is given intravenously over 120 minutes. On days 1 to 14 of each cycle, 40 mg / m 2 The dose of S-1 was administered orally twice daily (i.e., 40 mg / m in the morning). 2 and 40 mg / m at night 2 ).
[0554] The combination of bemarituzumab, SOX, and nivolumab was effective in treating gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in these patients, as measured by an objective response (defined as complete response (CR) + partial response (PR) as determined according to Response Evaluation Criteria in Solid Tumors [RECIST v1.1]).
[0555] Example 8: Treatment of patients with gastric cancer with bemarituzumab, CAPOX, and nivolumab
[0556] A group of patients with pathologically confirmed locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with FGFR2b overexpression were treated with bemarituzumab at one of the following doses:
[0557] (1) a dose of 15 mg / kg administered intravenously on Day 1 (D1) of Cycle 1 and Q3W thereafter, and a single dose of 7.5 mg / kg administered on Day 8 of Cycle 1; or
[0558] (2) A dose of 22 mg / kg was administered intravenously on D1 of Cycle 1 and Q3W thereafter, and a single dose of 11 mg / kg was administered on Day 8 of Cycle 1.
[0559] These patients were also treated with nivolumab after the completion of the bemarituzumab infusion. Nivolumab was administered intravenously over 30 minutes (±10 minutes) on Day 1 of each cycle at a dose of 360 mg.
[0560] In addition, these patients were treated with CAPOX after the completion of the nivolumab infusion. Specifically, oxaliplatin was administered at 130 mg / m on day 1 of each cycle. 2 The dose is given intravenously over 120 minutes. On days 1 to 14 of each cycle, 1000 mg / m 2 Capecitabine was administered orally twice daily (i.e., 1000 mg / m in the morning). 2 and 1000 mg / m at night 2 ).
[0561] The combination of bemarituzumab, CAPOX, and nivolumab was effective in treating gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in these patients, as measured by progression-free survival and / or overall survival.
[0562] Example 9: Treatment of patients with gastric cancer with bemarituzumab, SOX, and nivolumab
[0563] A group of patients with pathologically confirmed locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with FGFR2b overexpression were treated with bemarituzumab at one of the following doses:
[0564] (1) a dose of 15 mg / kg administered intravenously on Day 1 (D1) of Cycle 1 and Q3W thereafter, and a single dose of 7.5 mg / kg administered on Day 8 of Cycle 1; or
[0565] (2) A dose of 22 mg / kg was administered intravenously on D1 of Cycle 1 and Q3W thereafter, and a single dose of 11 mg / kg was administered on Day 8 of Cycle 1.
[0566] These patients were also treated with nivolumab after the completion of the bemarituzumab infusion. Nivolumab was administered intravenously over 30 minutes (±10 minutes) on Day 1 of each cycle at a dose of 360 mg.
[0567] In addition, these patients were treated with SOX after the completion of the nivolumab infusion. Specifically, oxaliplatin was administered at 130 mg / m on day 1 of each cycle. 2 The dose is given intravenously over 120 minutes. On days 1 to 14 of each cycle, 40 mg / m 2 The dose of S-1 was administered orally twice daily (i.e., 40 mg / m in the morning). 2 and 40 mg / m at night 2 ).
[0568] The combination of bemarituzumab, SOX, and nivolumab was effective in treating gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in these patients, as measured by progression-free survival and / or overall survival.
[0569] Example 10: Results of a Phase 1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Bemarituzumab in Combination with Other Anticancer Therapies in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer
[0570] The anti-FGFR2b antibody bemarituzumab (Bema) was administered intravenously to three cohorts of patients with pathologically confirmed FGFR2b-overexpressing locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with or without nivolumab (Nivo) in combination with CAPOX according to the regimen described in Example 1. Specifically, two dose levels of bemarituzumab (i.e., cohort A dose level 1 (DL1) and cohort A DL2) were tested in cohort A and cohort C as described in Example 1 according to the following dosing regimen:
[0571] Queue A DL1 : Bema 15 mg / kg IV Q3W + single 7.5 mg / kg dose + CAPOX on Cycle 1 Day 8 ("C1D8") (N=6; pharmacokinetic (PK) data available for 6 / 6 patients)
[0572] Queue A DL2 : Bema 22 mg / kg IV Q3W + single 11 mg / kg dose of C1D8 + CAPOX (N=4; PK data available for 4 / 4 patients)
[0573] Queue C : Bema 22 mg / kg IV Q3W + single 11 mg / kg dose of C1D8 + CAPOX + Nivo (N=6; PK data available for 6 / 6 patients).
[0574] Bemmarituzumab serum concentrations were measured at pre-specified time points and are shown in Table 3. A summary of the preliminary PK parameters of bemmarituzumab in treatment cycles 1 and 2 is shown in Table 12.
[0575] Table 12. Median C of DL1&2 in Cohort A and Cohort C in Cycle 1 and Cycle 2 最大 and C 谷 Conclusion
[0576]
[0577] No PK-related drug-drug interactions (DDIs) were observed between bemarituzumab and nivolumab in the setting of CAPOX. In addition, based on the known safety profile of bemarituzumab, no new safety findings were found in patients in Cohort A (DL1 and DL2) and Cohort C.
[0578] References
[0579] Each of the following references is incorporated herein by reference in its entirety.
[0580] International Committee of Medical Journal Editors,UniformRequirements for Manuscripts Submitted to Biomedical Journals:Writing andEditing for Biomedical Publication.2019.http: / / www.icmje.org /
[0581] Ahn S, Lee J, Hong M, et al. FGFR2 in gastric cancer: proteinoverexpression predicts gene amplification and high H-index predicts poorsurvival. Mod Pathol. 2016; 29(9):1095-1103.
[0582] Al-Batran SE,Hartmann JT,Hofheinz R,et al.Biweekly Fluorouracil,Leucovorin,Oxaliplation and Docetaxel(FLOT) for Patients with MetastaticAdenocarcinoma of the Stomach or Esophagogastric Junction:A Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie.Annals of Oncology.2008;19:1882-1887.
[0583] Andre F,Ranson M,Dean E,et al.Abstract LB-145:Results of a Phase IStudy of AZD4547,an Inhibitor of Fibroblast Growth Factor Receptor(FGFR),inPatients with Advanced Solid Tumors.AACR 104th Annual Meeting 2013,Washington,DC,American Association of Cancer Research.
[0584] Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combinationwith chemotherapy versus chemotherapy alone for treatment of HER2-positiveadvanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial[published correction appears in Lancet.2010Oct 16;376(9749):1302].Lancet.2010;376(9742):687-697.
[0585] Bray F,Ferlay J,Soerjomataram I,Siegel RL,Torre LA,Jemal A.Globalcancer statistics 2018:GLOBOCAN estimates of incidence and mortalityworldwide for 36 cancers in 185 countries.CA Cancer J Clin.2018 Nov;68(6):394-424.
[0586] Blum M,Suzuki A,Ajani JA.A comprehensive review of S-1 in thetreatment of advanced gastric adenocarcinoma.Future Oncology.2011;7(6).
[0587] Boku N,Ryu M-H,Kato K,et al.Safety and efficacy of nivolumab incombination with S-1 / capecitabine plus oxaliplatin in patients withpreviously untreated,unresectable,advanced,or recurrent gastric / gastroesophageal junction cancer:interim results of a randomized,phase IItrial(ATTRACTION-4).Ann Oncol.2019;30(2):250-258.
[0588] Boku N,Yamamoto S,Fukuda S,et al.Fluorouracil versus combination oririnotecan plus cisplatin versus S-1 in metastatic gastric cancer:arandomized phase 3 study.The Lancet.2009;10(11):P1063-P1069.
[0589] Brookmeyer,R.and Crowley,J.A confidence interval for the mediansurvival time.Biometrics.1982;38:29-41.
[0590] Brown AP,Courtney CL,King LM,et al.Cartilage Dysplasia and TissueMineralization in the Rat Following Administration of a FGF Receptor TyrosineKinase Inhibitor.Toxicologic Pathology.2005;33:449-455.
[0591] Catenacci DVT,Rasco D,Lee J,et al.Phase I Escalation and ExpansionStudy of Bemarituzumab(FPA144)in Patients with Advanced Solid Tumors andFGFR2b Selected Gastroesophageal Adenocarcinoma.J Clin Oncol.2020;82(21):2418-2426.
[0592] Clopper,CJ and Pearson ES.The use of confidence or fiducial limitsillustrated in the case of the binomial.Biometrika.1934:404–416.
[0593] Dienstmann R,Bahleda R,Barbara A,et al.First in human study of JNJ-42756493,a potent pan fibroblast growth factor receptor(FGFR)inhibitor inpatients with advanced solid tumors.AACR 105th Annual Meeting 2014,San Diego,CA.
[0594] Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluationcriteria in solid tumours:revised RECIST guideline(version 1.1).Eur JCancer.2009;45(2):228-247.
[0595] Fuchs C,Tomasek J,Yong C,et al.Ramucirumab Monotherapy for PreviouslyTreated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma(REGARD):an International,Randomised,Multicentre,Placebo-Controlled,Phase 3Trial.Lancet Oncology.2014;383:31-39.
[0596] GASTRIC(Global Advanced / Adjuvant Stomach Tumor Research InternationalCollaboration)Group,Paoletti X,Oba K,et al.Benefit of adjuvant chemotherapyfor resectable gastric cancer:a meta-analysis.JAMA.2010;303(17):1729-1737.
[0597] Gemo A,Deshpande A,Palencia S,et al.FPA144:A Therapeutic Antibody forTreating Ptients with Gastric Cancers Bearing FGFR2 Gene Amplification.AACR105th Annual Meeting 2014,San Diego California.
[0598] Janjigian YY,Shitara K,Moehler M,et al.First-line nivolumab pluschemotherapy versus chemotherapy alone for advanced gastric,gastro-oesophageal junction,and oesophageal adenocarcinoma(CheckMate 649):arandomized,open-label,phase 3 trial.Lancet.2021;398(10294):27-40.
[0599] Jung EJ,Jung EJ,Min SY,Kim MA,Kim WH.Fibroblast growth factorreceptor 2 gene amplification status and its clinicopathologic significancein gastric carcinoma.Hum Pathol.2012;43(10):1559-1566.
[0600] Kalbfleisch,J.D.and Prentice,R.L.(1980)The statistical analysis offailure time data.John Wiley and Sons,New York.
[0601] Kang YK,Kang WK,Shin DB,et al.Capecitabine / Cisplatin Versus5Fluorouracil / Cisplatin as First-Line Therapy in Patients with AdvancedGastric Cancer:A Randomised Phase III Noninferiority Trial.Annals ofOncology.2009;20:666-673.
[0602] Katoh Y and Katoh M.Hedgehog signaling pathway and gastrointestinalstemcell signaling network(review).Int J Mol Med.2006;18(6):1019-1023.
[0603] KimGM,Jeung H-C,Rha SY,et al.A randomized phase III trial of S-1-oxaliplatinversus cepecitabine-oxaliplatin in advanced gastric cancer.Eur JCancer.2012;48(4):518-526.
[0604] Keam B,ImSA,Han SW,et al.Modified FOLFOX-6 chemotherapy in advancedgastric cancer:Results of phase II study and comprehensive analysis ofpolymorphisms as a predictive and prognostic marker.BMC Cancer.2008;8:148.
[0605] KimHS,Kim JH,Jang HJ,Han B,Zang DY.Pathological and PrognosticImpacts of FGFR2 Overexpression inGastric Cancer:A Meta-Analysis.JCancer.2019;10(1):20-27.Published 2019 Jan 1.
[0606] Matsumoto K,Arao T,Hamaguchi T,et al.FGFR2 gene amplification andclinicopathological features in gastric cancer.Br J Cancer.2012;106(4):727-732.
[0607] Moehler M,Shitara K,Garrido M,et al.LBA6_PR Nivolumab(nivo)pluschemotherapy(chemo)versus chemo as first-line(1L)treatment for advancedgastric cancer / gastroesophageal junction cancer(GC / GEJC) / esophagealadenocarcinoma(EAC):First results of the CheckMate 649 study.Ann Oncol.2020;31:S119110.1016 / j.annonc.2020.08.2296.
[0608] National Cancer Institute(2015).SEER Stat Fact Sheets:StomachCancer.Retrieved February 25,2016,from http: / / seer.cancer.gov / statfacts / html / stomach.html.
[0609] National Comprehensive Cancer Network,NCCN Guidelines for GastricCancer 2021.https: / / www.nccn.org / guidelines / guidelines-detail?category=1&id=1434.
[0610] Okines AFC,Norman AR,McCloud P,Kang YK,Cunningham D.Meta-analysis ofthe REAL-2 and ML17032 trials:evaluating capecitabine-based combinationchemotherapy and infused 5-fluorouracil-based combination chemotherapy forthe treatment of advanced oesophago-gastric cancer.Ann Oncol.2009;20(9):15291534.
[0611] Park YH,Lee J-L,Ryoo B-Y,et al.Capecitabine in combination withoxaliplatin(XELOX)as a first-line therapy for advanced gastric cancer.CancerChemother Pharmacol.2008;61(4):623-629.
[0612] Sequist LV,Cassier P,Varga A,et al.Phase I Study of BGJ398,aSelective Pan-FGFR Inhibitor in Genetically Preselected Advanced SolidTumors.AACR 2014 Annual Meeting,San Diego,CA.
[0613] Shah MA,Kang YK,Thuss-Patience PC,et al.Biomarker analysis of theGATSBY study of trastuzumab emtansine versus a taxane in previously treatedHER2 positive advanced gastric / gastroesophageal junction cancer.GastricCancer.2019;22(4):803-816.
[0614] Shinkawa T,Nakamura K,Yamane N,et al.The Absence of Fucose but Notthe Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity.J Biol Chem.2003;278(5):3466-3473.
[0615] Shitara K,Doi T,Dvorkin M,et al.Trifluridine / tipiracil versus placeboin patients with heavily pretreated metastatic gastric cancer(TAGS):arandomised,double-blind,placebo-controlled,phase 3 trial.Lancet Oncol.2018;19(11):1437-1448.
[0616] The GASTRIC Group.Benefit of Adjuvant Chemotherapy for ResectableGastric Cancer.JAMA.2010;303(1729-1737):1729.
[0617] Tokunaga R,Imamura Y,Nakamura K,et al.Fibroblast growth factorreceptor 2expression,but not its genetic amplification,is associated withtumor growth and worse survival in esophagogastric junctionadenocarcinoma.Oncotarget.2016;7(15):19748-19761.
[0618] Waddell T,Verheij M,Allum W,et al.Gastric Cancer:ESMO-ESSO-ESTROClinical Practice Guidelines for Diagnosis,Treatment,and Follow-up.Radiotherapy and Oncology.2014;110:189-194.
[0619] Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, FleigWE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24(18): 2903-2909.
[0620] Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochraine Database Syst Rev. 2017;8(8):CD004064.
[0621] Yamada Y,Higuchi K,Nishikawa K,et al.Phase III Study comparingoxaliplatin plus S-1with cisplatin plus S-1in patients with advanced gastric cancer.Ann Oncol.2014;26(1):141-148.
[0622] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[0623] Unless otherwise indicated herein or clearly contradicted by the context, the use of the terms "one" and "a kind of" and "the" and "at least one" and similar indicators in the context of describing the present invention (particularly in the context of the following claims) will be interpreted as covering both the singular and the plural. The use of the term "at least one" followed by a list of one or more items (e.g., "at least one of A and B") should be interpreted as indicating one item selected from the listed items (A or B) or any combination of two or more listed items (A and B), unless otherwise indicated herein or clearly contradicted by the context. Unless otherwise indicated, the terms "comprising", "having", "including" and "containing" will be considered open terms (i.e., meaning "including but not limited to"). Unless otherwise indicated herein, the statements of the range of values herein are intended to be used only as a shorthand method of referring to each independent value within the range individually, and each independent value is incorporated into the specification as if the value were individually stated herein. Unless otherwise indicated herein or clearly contradicted by the context, all methods described herein can be performed in any suitable order. The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to better describe the invention and does not impose limitations on the scope of the invention unless otherwise required. No language in this specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0624] Preferred embodiments of the present invention are described herein, including the best mode known to the inventor for implementing the present invention. After reading the above description, the changes of those preferred embodiments are obvious to those of ordinary skill in the art. The inventor expects that a skilled person will appropriately adopt such changes, and the inventor intends to practice the present invention in a manner other than that clearly described herein. Therefore, the present invention includes all modifications and equivalents of the subject matter listed in the appended claims as permitted by applicable law. In addition, unless otherwise indicated herein or clearly contradictory to the context, the present invention covers any combination of the above-mentioned elements in all possible variations thereof.
Claims
1. A method for treating gastric cancer in a subject, the method comprising: administering an anti-FGFR2b antibody to the subject; as well as The subject is administered a chemotherapy regimen comprising: (a) oxaliplatin and capecitabine; or (b) Oxaliplatin and S-1.
2. The method of claim 1, wherein the anti-FGFR2b antibody is administered Q3W at a dose of at least 15 mg / kg.
3. The method of claim 1, wherein the anti-FGFR2b antibody is administered Q3W at a dose of 15-22 mg / kg or greater than 15 mg / kg to no more than 22 mg / kg.
4. The method of claim 2 or claim 3, further comprising administering an additional dose of 5-15 mg / kg of the anti-FGFR2b antibody 7-10 days after the first Q3W administration of the anti-FGFR2b antibody.
5. The method of claim 4, wherein the additional dose of the anti-FGFR2b antibody is 6-9 mg / kg or 7-8 mg / kg.
6. The method of claim 1, wherein the anti-FGFR2b antibody is administered Q3W at a dose of at least 20 mg / kg.
7. The method of claim 6, wherein the anti-FGFR2b antibody is administered Q3W at a dose of 20-30 mg / kg or 22-25 mg / kg or greater than 22 mg / kg to no more than 30 mg / kg or greater than 22 mg / kg to no more than 25 mg / kg.
8. The method of claim 6 or 7, further comprising administering an additional dose of 10-15 mg / kg of the anti-FGFR2b antibody 7-10 days after the first Q3W administration of the anti-FGFR2b antibody.
9. The method of claim 8, wherein the additional dose of the anti-FGFR2b antibody is 9-13 mg / kg or 10-12 mg / kg.
10. The method of any one of claims 1-9, wherein the anti-FGFR2b antibody is administered intravenously.
11. The method of any one of claims 1 to 10, comprising administering at least 65 mg / m 2 The oxaliplatin is administered intravenously at a dose of at least 500 mg / m 2 The capecitabine was administered orally at a dose of twice a day.
12. The method of claim 11, wherein the oxaliplatin is administered at 100-150 mg / m 2The dose of capecitabine was administered intravenously Q3W at 750-1500 mg / m 2 The dose is administered orally twice a day.
13. The method of any one of claims 1 to 10, comprising administering at least 65 mg / m 2 The oxaliplatin is administered intravenously at a dose of at least 20 mg / m 2 The S-1 was administered orally at a dosage of twice a day.
14. The method of claim 13, wherein the oxaliplatin is administered at 100-150 mg / m 2 The dose is administered intravenously Q3W, and the S1 is 30-60 mg / m 2 The dose is administered orally twice a day.
15. The method of claim 1, wherein the anti-FGFR2b antibody is administered intravenously at a dose of 15-22 mg / kg Q3W, and is further administered at an additional dose of 7-12 mg / kg 7-10 days after the first Q3W administration of the anti-FGFR2b antibody, and Wherein the chemotherapy regimen administered comprises: (a) 100-150 mg / m 2 The oxaliplatin was administered intravenously at a dose of 750-1500 mg / m 2 The capecitabine is administered orally twice a day at a dose of; or (b) 10-150 mg / m 2 The oxaliplatin was administered intravenously at a dose of 30-60 mg / m 2 The S-1 was administered orally at a dosage of twice a day.
16. The method of claim 1, wherein the anti-FGFR2b antibody is administered intravenously Q3W at a dose of 15-22 mg / kg and is further administered at an additional dose of 7-12 mg / kg 7-10 days after the first administration of the anti-FGFR2b antibody in the Q3W regimen, and Wherein the chemotherapy regimen administered comprises: (a) 130 mg / m 2 The oxaliplatin was administered intravenously at a dose of 1000 mg / m 2 The capecitabine is administered orally twice a day at a dose of; or (b) 130 mg / m 2 The oxaliplatin was administered intravenously at a dose of 40 mg / m 2 The S-1 was administered orally at a dosage of twice a day.
17. The method of claim 1, wherein the anti-FGFR2b antibody is administered intravenously at a dose of 22-30 mg / kg Q3W and is further administered at an additional dose of 10-12 mg / kg 7-10 days after the first Q3W administration of the anti-FGFR2b antibody, and Wherein the chemotherapy regimen administered comprises: (a) 130 mg / m 2 The oxaliplatin was administered intravenously at a dose of 1000 mg / m 2 The capecitabine is administered orally twice a day at a dose of; or (b) 130 mg / m 2 The oxaliplatin was administered intravenously at a dose of 40 mg / m 2 The S-1 was administered orally at a dosage of twice a day.
18. The method of any one of claims 1-17, further comprising administering an anti-PD-1 or anti-PD-L1 antibody to the subject.
19. The method of claim 18, wherein the anti-PD-1 or anti-PD-L1 antibody is administered Q3W.
20. The method of claim 18 or 19, wherein the anti-PD-1 antibody comprises nivolumab, pembrolizumab, or cemiplimab, or wherein the anti-PD-L1 antibody comprises atezolizumab, avelumab, or durvalumab.
21. The method of any one of claims 1-17, further comprising administering nivolumab to the subject at a dose of at least 300 mg Q3W.
22. The method of claim 21, wherein the nivolumab is administered at a dose of 300 mg-400 mg Q3W.
23. The method of claim 21, wherein the nivolumab is administered at a dose of 360 mg Q3W.
24. The method of any one of claims 1-23, wherein the anti-FGFR2b antibody comprises: a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 6, a HCDR2 of SEQ ID NO: 7, and a HCDR3 of SEQ ID NO: 8; and A light chain variable region comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO:9, LCDR2 of SEQ ID NO:10, and LCDR3 of SEQ ID NO:
11.
25. The method of claim 24, wherein the anti-FGFR2b antibody is afucosylated.
26. The method of any one of claims 24-25, wherein the heavy chain variable region of the anti-FGFR2b antibody comprises an amino acid sequence at least 95% identical to SEQ ID NO:4, and wherein the light chain variable region of the anti-FGFR2b antibody comprises an amino acid sequence at least 95% identical to SEQ ID NO:
5.
27. The method of any one of claims 24-26, wherein the heavy chain variable region of the anti-FGFR2b antibody comprises the amino acid sequence of SEQ ID NO:4, and wherein the light chain variable region of the anti-FGFR2b antibody comprises the amino acid sequence of SEQ ID NO:
5.
28. The method of any one of claims 24-27, wherein the anti-FGFR2b antibody comprises a heavy chain of SEQ ID NO: 1 and a light chain of SEQ ID NO:
2.
29. The method of any one of claims 1-28, wherein the anti-FGFR2b antibody is bemarituzumab.
30. The method of any one of claims 1-29, wherein the gastric cancer cells overexpress FGFR2b.
31. The method of any one of claims 1-30, wherein the gastric cancer cells overexpress FGFR2b mRNA or protein, or contain FGFR2 gene amplification.
32. The method of claim 30 or 31, wherein the gastric cancer cells overexpress FGFR2b as determined by immunohistochemistry (IHC).
33. The method of any one of claims 30-32, wherein at least 5%, 10%, 15% or 20% of the cells of the gastric cancer express FGFR2b as determined by IHC.
34. The method of any one of claims 30-32, wherein the gastric cancer cells have a FGFR2b staining intensity of at least 2+ or 3+, as determined by IHC, such as at least 5%, 10%, 15% or 20% of the gastric cancer cells have the FGFR2b staining intensity.
35. The method of any one of claims 30-32, wherein any cell of the gastric cancer has a FGFR2b staining intensity of at least 2+ or 3+ as determined by IHC.
36. The method of any one of claims 30-32, wherein at least 10% of the gastric cancer cells have a FGFR2b staining intensity of at least 2+ or 3+ as determined by IHC.
37. The method of any one of claims 1-36, wherein the chemotherapy regimen comprises (a) oxaliplatin and capecitabine.
38. The method of any one of claims 1-37, wherein the gastric cancer comprises gastric cancer or gastroesophageal junction cancer.
Citation Information
Patent Citations
Apparatus and process for electrolysis using a cation-permselective membrane and turbulence inducing means
EP0002009A1
Afucosylated Anti-FGFR2iiib antibodies
US20150050273A1
Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US8008449B2
Monoclonal antibodies to fibroblast growth factor receptor 2
US8101723B2
Compressed gas store for underground compressed gas storage
WO2015007600A1
